Studies of enzymes in mitochondrial DNA precursor synthesis by Sun, Ren
Studies of Enzymes in Mitochondrial 
DNA Precursor Synthesis 
Regulatory Mechanisms for Human Thymidine Kinase 2 
and Deoxyguanosine Kinase 
Ren Sun 
Faculty of Veterinary Medicine and Animal Science 
Department of Anatomy, Physiology and Biochemistry 
Uppsala 
  
Doctoral Thesis 
Swedish University of Agricultural Sciences 
Uppsala 2013 Acta Universitatis agriculturae Sueciae 
2013:64 
ISSN 1652-6880 
ISBN (print version) 978-91-576-7866-9 
ISBN (electronic version) 978-91-576-7867-6 
© 2013 Ren Sun, Uppsala 
Print: SLU Service/Repro, Uppsala 2013 
Cover: Yin yang bagua arrangement 
(photo: adopted from Wikimedia Commons) Studies of Enzymes in Mitochondrial DNA Precursor Synthesis - 
Regulatory Mechanisms for Human Thymidine Kinase 2 and 
Deoxyguanosine Kinase 
Abstract 
As important enzymes in mitochondrial nucleotide salvage pathway, thymidine kinase 
2 (TK2) and deoxyguanosine kinase (dGK) are expressed constitutively in almost all 
cells. These two enzymes catalyze the initial rate-limiting phosphorylation of 
pyrimidine and purine deoxynucleosides, respectively, providing DNA precursors for 
mitochondrial DNA (mtDNA) replication. 
Inherited genetic defects in TK2 have been associated with infantile myopathic form 
of mtDNA depletion syndrome (MDS). In study I, two mutations, R225W and a novel 
T230A, in TK2 are identified as a new genetic cause of adult-onset autosomal recessive 
progressive external ophthalmoplegia (arPEO) and the kinetic and structural effects of 
the two mutations on enzyme function have been characterized. 
Nucleoside analogs are widely used in anti-viral and anti-cancer chemotherapy, but 
they can cause severe side-effect such as mtDNA depletion. In study II, the potential 
mechanism underlying pyrimidine nucleoside analogs-associated mitochondrial 
toxicities was investigated, and showed that thymidine analogs had opposite effects on 
dThd and dCyd phosphorylation and thus can inhibit dThd salvage, leading to 
imbalanced dTTP and dCTP pools. It was found that the mechanism is most likely due 
to that TK2 normally exists in an inactive form with bound dTTP. 
The redox regulation of TK2 and dGK was studied in study III and IV. The activity 
of both enzymes was sensitive to the cellular redox status. Under oxidative stress, both 
TK2 and dGK can be reversibly S-glutathionylated by GSSG. The modification of the 
conserved Cys189 in TK2 was responsible for a partial inactivation and selective 
degradation of TK2 in mitochondria, most likely via the AAA
+ Lon protease. The 
oxidative effect of nucleoside analogs was also evaluated. Treatment with 3’-azido-
2’,3’-dideoxythymidine (AZT) and 2’,3’-dideoxyinosine (ddI) led to degradation of 
mitochondrial TK2 and dGK, whereas uridine and guanosine supplementations to AZT 
respective ddI treatments prevented both proteins from degradation. 
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1 Introduction 
1.1 DNA  precursors  metabolism 
Nucleotides, the precursors of RNA and DNA, i.e., ribonucleoside and 
deoxyribonucleoside phosphates, are involved in almost all aspects of cellular 
metabolism, including acting as carriers of activated metabolites for 
biosynthesis, metabolic regulators, storages of chemical energy, and structural 
moieties of coenzymes either alone or in combination with other molecules. 
For instance, cyclic adenosine monophosphate (cAMP) acts as a second 
messenger in the signal transduction pathway, while adenosine triphosphate 
(ATP) is the ubiquitous intracellular energy currency acting as a cosubstrate in 
many enzymatic energy-requiring processes (Nygaard & Saxild, 2009).  
A nucleotide is composed of a five-carbon sugar - ribose or deoxyribose, 
one or more phosphoryl groups, and one nitrogenous base which can be 
divided into two families: purine bases including adenine (A) and guanine (G) 
and pyrimidine bases including cytosine (C), thymine (T), and uracil (U). 
Thymine is found exclusively in DNA, while uracil is in RNA. The addition of 
a base to a ribose or 2-deoxyribose creates a ribonucleoside, which is found in 
RNA, or a deoxyribonucleoside, which is a constituent of DNA. The 
attachment of one phosphate group to the 5’-hydroxyl group of the pentose 
moiety generates a nucleoside monophosphate (NMP/dNMP). The additions of 
the second and third phosphoryl groups to nucleoside monophosphate result in 
nucleoside diphosphates (NDP/dNDP) and triphosphates (NTP/dNTP). 
Different from nucleosides, nucleotides are negative charged because of the 
phosphate groups. 
With the exceptions of some bacteria and parasitic protozoa, nucleotides 
within most organisms and cells are generated by two distinct biosynthetic 
routes  i.e., the de novo pathway and the salvage pathway (Traut, 2001).   
Nucleotides synthesized de novo can meet the large demand for DNA/RNA 
precursors in growing and proliferating cells, whereas pre-formed nucleosides 12 
and bases can be recycled by the salvage pathway to maintain the nucleotide 
pools with less energy consumption (Zrenner et al., 2006). Both the synthetic 
pathways and nucleotide catabolism pathways are presented briefly in the 
following sections. 
1.1.1 The de novo biosynthesis of deoxyribonucleotides 
Both purine and pyrimidine rings can be synthesized de novo from low 
molecular weight precursors, e.g., CO2, glutamine and aspartic acid through 
many enzymatic reactions, which consume considerable energy provided 
predominantly by ATP. Serving as a source of ribose and phosphate, 5-
phosphoribosyl-1-pyrophosphate (PRPP) is a common and essential precursor 
for purine and pyrimidine nucleotide biosynthesis. It is synthesized from ribose 
5-phosphate and ATP, and the reaction is catalyzed by PRPP synthetase 
(ribose-phosphate pyrophosphokinase). It is notable that PRPP participates in 
not only the de novo pathway of nucleotide biosynthesis, but also the salvage 
of nucleobases.   
Synthesis of purine nucleotides 
The heterocyclic purine ring is assembled on ribose 5-phosphate donated by 
PRPP. The atoms of the base moiety originate from CO2, glycine, aspartate, 
glutamine, and N
10-formyl-tetrahydrofolate, forming the purine structure. The 
initial product of purine biosynthesis is inosine 5’-monophosphate (IMP or 
inosinate), which is generated by ten successive reactions. IMP is then 
converted in two additional steps to adenosine 5’-monophosphate (AMP) or 
guanosine 5’-monophosphate (GMP), both of which can be further 
phosphorylated to the diphosphate forms (NDP) by base-specific nucleoside 
monophosphate kinases (NMPKs), i.e., adenylate kinase (AMPK) and 
guanylate kinase (GMPK). Nucleoside diphosphate kinase (NDPK) catalyzes 
the phosphorylation of NDP to the corresponding NTP and there are several 
isoforms present in different cell compartments (Figure 1) (Traut, 1988).  
DNA precursors, namely 2’-deoxyribonucleotides, are synthesized by the 
reduction of ribonucleotides. In mammalian cells, this is the committed step in 
the dNTPs de novo synthesis and it is catalyzed by ribonucleotide reductase 
(ribonucleoside diphosphate reductase, RNR), which reduces ribonucleoside 
diphosphate (NDP) to deoxyribonucleoside diphosphate (dNDP). The products 
dADP, dGDP, dUDP and dCDP are converted to dATP, dGTP, dUTP and 
dCTP by NDPK (Figure 1). 
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Figure 1. An overview of DNA precursor synthesis. Abbreviations: TK1, thymidine kinase 1; 
dCK, deoxycytidine kinase; TK2, thymidine kinase 2; dGK, deoxyguanosine kinase; 
TMPK/GMPK/AMPK and UMP-CMPK, thymidylate/guanylate/adenylate kinase and UMP-CMP 
kinase; NMPKs, nucleoside monophosphate kinases; NDPKs, nucleoside diphosphate kinases; TS, 
thymidylate synthase; dUTPase, dUTP nucleotidohydrolase; R1/R2/p53R2, large/small/p53-
inducible small subunit of ribonucleotide reductase. 
Synthesis of pyrimidine nucleotide 
Pyrimidine bases are generated in the form of orotate from CO2, glutamine, 
and aspartate, prior to being attached to the ribose 5-phosphate of PRPP. The 
newly synthesized pyrimidine ring is then converted to orotidine 5’-
monophosphate (OMP) by orotate phosphoribosyltransferase with PRPP as the 
ribose phosphate donor. Thereafter, OMP is decarboxylated to form uridine 14 
monophosphate (UMP), which can be further phosphorylated to uridine 
di/triphosphate (UDP/UTP). Cytidine triphosphate (CTP) is synthesized from 
UTP by CTP synthetase (Jones, 1980).  
Different from the de novo generation of deoxycytidylate described above, 
thymidine monophosphate (dTMP) is synthesized from dUMP by thymidylate 
synthase (TYMS or TS) with N
5,N
10-methylene tetrahydrofolate as the methyl 
donor and successively phosphorylated into dTTP by thymidylate kinase 
(TMPK) and NDPK as shown in Figure 1 (Costi, 1998). 
1.1.2 The  salvage  pathway 
Nucleotides can also be synthesized from the salvage of bases and nucleosides 
originating from the diet and normal turnover of cellular nucleic acids. In 
organisms lacking the de novo pathway, salvage of purine and pyrimidine is an 
essential process. In most tissues of mammals the salvage pathway also plays a 
vital role in the maintenance and regulation of intracellular nucleotide pools 
(Figure 1). Free purine bases can be converted directly to mononucleotides 
with PRPP as the ribose 5-phosphate source by two enzymes: (i) hypoxanthine-
guanine phosphoribosyltransferase which directly converts guanine and 
hypoxanthine to GMP and IMP, and (ii) adenine phosphoribosyltransferase 
which salvages adenine to AMP (Nyhan, 2001). Recycling of nucleosides is 
facilitated by a variety of kinases. Uridine-cytidine kinase is involved in the 
utilization of pyrimidine nucleosides, catalyzing the phosphorylation of uridine 
and cytidine to UMP and CMP, and adenosine kinase catalyzes the 
phosphorylation of Ado to AMP (Van Rompay et al., 2001; Spychala et al., 
1996). The salvage of deoxynucleosides is catalyzed by deoxynucleoside 
kinases,  e.g., cytosolic thymidine kinase 1 (TK1) and deoxycytidine kinase 
(dCK), mitochondrial thymidine kinase 2 (TK2) and deoxyguanosine kinase 
(dGK) (Figure 1). TK1 catalyzes the initial phosphorylation of dThd and dUrd, 
while dCK phosphorylates dCyd, dAdo and dGuo to dCMP, dAMP and dGMP. 
In mitochondria, purine nucleosides (dAdo, dGuo, and dIno) and pyrimidine 
nucleosides (dThd, dCyd, and dUrd) are phosphorylated to the corresponding 
nucleoside 5’-monophosphates by dGK and TK2, respectively. These enzymes 
have different substrate specificities and subcellular localizations and the 
characteristics of the enzymes are discussed in detail in the next section (Figure 
1) (Arner & Eriksson, 1995).  
1.1.3  Purine and pyrimidine catabolism 
A fraction of free purines and pyrimidines is recycled via the salvage pathway, 
whereas excess nucleosides and their metabolites must be catabolized in order 
to maintain the homeostasis of the nucleotide pools and prevent the 15 
accumulation of free bases within cells. High levels of purines can be toxic to 
cells and tissues. 
The de-phosphorylation of nucleoside monophosphate (NMP/dNMP) is 
catalyzed by 5’-nucleotidases (5’-NTs), which include a family of enzymes e.g., 
mitochondrial and cytosolic 5’(3’)-deoxynucleotidases (Bianchi & Spychala, 
2003). In primates including humans, the end product of purine catabolism is 
uric acid, which is mainly formed in liver and excreted by the kidney into urine. 
Several enzymes are involved in purine degradation but the basic structure of 
the purine ring is not broken down. The ubiquitous purine nucleoside 
phosphorylase (PNP) enzyme breaks down purine nucleosides adenosine, 
guanosine, and inosine to purine bases and ribose/deoxyribose-1-phosphate 
(Bzowska et al., 2000). Guanine and hypoxanthine are then further converted 
to xanthine by guanine deaminase and xanthine oxidase (XDH), respectively. 
XDH also catalyzes the oxidation of xanthine to uric acid. In contrast, the 
catabolism of adenosine nucleotide requires additional step, e.g., deamination 
of adenosine and AMP by adenosine deaminase and AMP deaminase, 
respectively (Cristalli et al., 2001).  
In contrast to purine catabolism, pyrimidine ring can be completely 
degraded into β-amino acids, ammonia and CO2. Prior to the pyrimidine ring 
cleavage, pyrimidine nucleotides are hydrolyzed by 5’-NTs to the 
corresponding nucleosides, which are subsequently degraded into uracil (in the 
cases of CMP and UMP) and thymine (in case of dTMP) by cytidine 
deaminase, uridine phosphorylase, and thymidine phosphorylase, respectively. 
The ultimate breakdown of uracil and thymine is catalyzed by 
dihydropyrimidine dehydrogenase, dihydropyrimidinase, and ureidopropionase, 
and results in the generation of β-alanine and β-aminoisobutyrate, respectively. 
1.2  Basic properties of mammalian deoxyribonucleoside 
kinases (dNKs) 
With distinct intracellular compartmentalization and overlapping substrate 
specificities, mammalian deoxyribonucleoside kinases (dNKs), including 
thymidine kinase 1 and 2 (TK1 and TK2), deoxyguanosine kinase (dGK), and 
deoxycytidine kinase (dCK), catalyze the initial phosphorylation of 
deoxyribonucleosides as well as their analogs (Figure 1). This provides an 
alternative route for the synthesis of DNA precursors and contributes to a 
balanced supply of deoxyribonucleotides complementing the de novo synthesis 
pathway (Johansson et al., 2001; Arner & Eriksson, 1995). This reaction is 
usually the rate-limiting step in the salvage pathway and the products can be 
further phosphorylated to dNTP by NMPKs and NDPKs. In terminally 16 
differentiated or quiescent cells, due to the down-regulation of enzymes in the 
de novo biosynthesis of dNTPs, including ribonucleotide reductase (R1-R2) 
and TS, the dNKs play vital roles in the maintenance of intracellular dNTP 
pools for mitochondrial DNA (mtDNA) replication and nuclear DNA (nDNA) 
repair. Actually, dNKs, particularly TK2 and dGK are indispensable for 
mtDNA maintenance and deficiency in TK2 or dGK caused by genetic 
alternations results in tissue specific mtDNA depletion syndrome (MDS) and 
progressive external ophthalmoplegia (PEO) (Ronchi et al., 2012; Tyynismaa 
et al., 2012; Wang, 2010; Wang & Eriksson, 2010). Meanwhile, many 
nucleoside analogs used in chemotherapy of viral infections and cancers are 
administrated as pro-drugs and are dependent on the intracellular 
phosphorylation by dNKs to be pharmacologically active. Therefore, dNKs 
have gained special interests in the medical perspective. In the following 
sections, basic properties of the four mammalian dNKs are described with 
focus on mitochondrial TK2 and dGK.  
1.2.1  Thymidine kinase 1 (TK1, E.C. 2.7.1.21) 
Human thymidine kinase 1 (ATP:thymidine 5’-phosphotransferase) is a 
cytosolic deoxyribonucleoside kinase, encoded by the TK1 gene, which spans 
12.9 kb on chromosome 17q25.2-25.3 and consists of seven exons. TK1 exists 
as homodimers (ca 50 kDa) and/or homotetramers (ca 100 kDa) with a subunit 
size of 24-25 kDa (Munch-Petersen, 2010; Munch-Petersen et al., 1993). 
Compared with the other mammalian dNKs, TK1 has many distinctive 
characteristics, e.g., this enzyme only catalyzes the phosphorylation of dThd 
(as well as dUrd), and thus it has a more restricted substrate specificity. The 
expression of TK1 is highly cell-cycle dependent with a similar profile as the 
DNA precursors pool: the level of cytosolic TK1 is very low or absent in 
resting cells or in early G1 phase, increases during G1/S transition, reaches a 
maximum in S phase, declines in G2/M phase and disappears during mitosis 
(Munch-Petersen, 2010; Chabes & Thelander, 2003). Ke et al. proved that the 
ubiquitin-proteasome pathway was responsible for the mitotic degradation of 
human TK1 (hTK1) (Ke & Chang, 2004). The regulation of hTK1 expression 
occurs at the transcriptional, translational and post-translational levels and is 
important for the formation of dTTP. However, the mechanism for regulation 
of TK1 expression is beyond the scope of this thesis and will not be further 
discussed. 
Although TK1 is found in almost all living organisms and has been widely 
studied, the most likely physiological role of this enzyme has not been resolved 
until recently when TK1 was found to play an important role in DNA repair 
(Chen et al., 2010). 17 
In addition, the diagnostic and prognostic potentials of TK1 as a biomarker 
of cell proliferation have been widely investigated and utilized in both human 
and veterinary medicine due to the tight correlation between TK1 level and cell 
proliferation. Increased TK1 activity and protein level in serum (sTK) have 
been found in different forms of cancers. Accordingly sTK has been used as a 
useful biomarker in health screening projects, for detection of potential and 
early-stage malignancies, detection of cancer progression, and as an efficacy 
marker for antitumor therapy (von Euler & Eriksson, 2011; O'Neill et al., 
2001). 
1.2.2  Deoxycytidine kinase (dCK, E.C. 2.7.1.74) 
Deoxycytidine kinase (dCK, NTP:deoxycytidine 5’-phosphotransferase) 
phosphorylates deoxycytidine, deoxyadenosine, deoxyguanosine and their 
analogs to their corresponding monophosphates with nucleoside triphosphates 
as phosphate donors. dCK plays an important role in overall dNTP metabolism 
and is a rate-limiting step for the activation of many nucleoside analogs, such 
as the anti-neoplastic agent 2-chlorodeoxyadenosine and the anti-viral analog 
2’-3’-dideoxycytidine (ddC) (Eriksson et al., 1995; Karlsson et al., 1994; Piro, 
1992). 
Human dCK is encoded by a single-copy gene of 34 kb located on 
chromosome 4 band q13.3-21.1 with 7 exons, encoding a polypeptide of 261 
amino acids (Song et al., 1993). Active dCK purified from various human 
tissues is a 60 kDa dimer (Bohman & Eriksson, 1988). The expression of dCK 
occurs in a tissue-specific manner, i.e., highest in lymphoid tissues, 
intermediate in proliferating cells, and lowest in differentiated tissues e.g., 
muscle, kidney and brain. The regulation of dCK expression is likely due to 
both post-transcriptional and post-translational mechanisms (Hazra et al., 2011; 
Eriksson et al., 2002; Arner & Eriksson, 1995; Hengstschlager et al., 1993).  
Similar to TK1, the biological function of dCyd kinase is enigmatic. Toy 
and coworkers found that T and B lymphopoiesis was impaired in dCK 
knockout mice, while the development of other tissues and organs was not 
affected (Toy et al., 2010). Inactivation of dCK was also reported to cause 
dCTP pool depletion, replication stress, and DNA replication arrest in early S-
phase in T and B lymphoid cells in dCK knock-out mice (Austin et al., 2012). 
That is in agreement with high dCK activity levels in lymphocytic tissues, thus 
demonstrating the role of dCK-associated dNTP synthesis pathways in certain 
tissues. Many studies of dCK are focused on its central role in the activation of 
nucleoside analog pro-drugs widely used in anti-cancer and anti-viral 
chemotherapy. With its broad substrate specificity dCK can phosphorylate 
dCyd analogs as well as several purine analogs, such as the anti-neoplastic 18 
drugs cytosine arabinoside (araC), 2’,2’-difluorodeoxycytidine (gemcitabine), 
2-chlorodeoxyadenosine (cladribine), and β-L-dioxolane-cytidine 
(troxacitabine), as well as the anti-viral drugs ddC and β-l-2’,3’-dideoxy-3’-
thiacytidine (lamivudine) (Sabini et al., 2003). The pivotal role of dCK in the 
clinical pro-drug activation is highlighted by the correlation between drug 
sensitivity and dCK activity in many target cells. Impaired dCK function has 
been found in cells resistant to nucleoside analogs, such as araC and 
gemcitabine (Ruiz van Haperen et al., 1994; Owens et al., 1992). 
1.2.3  Thymidine kinase 2 (TK2, E.C. 2.7.1.21) 
Thymidine kinase 2 (ATP:thymidine 5’-phosphotransferase), is the 
mitochondrial thymidine kinase responsible for salvaging pyrimidine 
deoxyribonucleosides, dThd, dUrd, and dCyd to yield the corresponding 5’-
monophosphates, utilizing ATP or CTP as phosphate donors. Both dTTP and 
dCTP act as feedback inhibitors (Arner & Eriksson, 1995; Berk & Clayton, 
1973). TK2 is encoded by a nuclear gene on chromosome 16q22 and mature 
TK2 is predominantly localized in mitochondria (Munch-Petersen, 2010; Wang 
& Eriksson, 2000; Johansson & Karlsson, 1997; Willecke et al., 1977). 
Generally, TK2 is assumed to be expressed constitutively in nearly all tissues, 
in close correlation to their mitochondrial contents, but irrespective of cell 
cycles (Wang et al., 1999; Arner & Eriksson, 1995). Wang et al. found that rat 
mt TK2 activity showed a tissue-specific distribution and was highest in brain, 
lung and spleen, intermediate in heart, kidney and liver, and lowest in skeletal 
muscle (Wang, 2010). In proliferating cells, TK2 level is much lower than the 
level of cytosolic TK1, whereas TK2 is the sole pyrimidine 
deoxyribonucleoside phosphorylating enzyme in post-mitotic tissues, where 
the  de novo biosynthesis of dNTPs and cytosolic TK1 are down-regulated 
(Eriksson & Wang, 2002; Wang et al., 1999). Consequently, TK2 appears to 
play a significant role in the constant and balanced supply of dNTPs for 
mtDNA replication and nDNA repair (Wang et al., 2003). Among the four 
mammalian dNKs, mitochondrial TK2 and dGK are the least investigated 
enzymes due to their mitochondrial localization and low abundance. 
Furthermore, the 3D-structure of TK2 has not yet been solved. 
Early studies on human TK2 were performed with partially purified 
proteins from human tissues such as leukemic spleen, placenta, liver, and brain 
and it was reported that TK2 was a 29 kDa monomer in the presence or 
absence of ATP or dThd (Jansson et al., 1992; Munch-Petersen et al., 1991). 
Studies on recombinant mouse TK2 showed that the active form of full-length 
mouse TK2 was a dimer (Wang & Eriksson, 2000). Analyzed by gel filtration 
analysis, recombinant human TK2 was also found to oligomerize to dimer and 19 
in rat liver mitochondrial extract several more complex forms were recently 
described (Sun et al., 2010). Therefore, it is still an open question which form 
of TK2 exists in vivo.  
Human TK2 cDNA (1930 bp) was cloned based on amino acid sequence 
information from a brain cDNA library and an open reading frame for TK2 
(699 bp) corresponding to 232 amino acid residues were found, without any 
coding region for a mitochondrial target sequence (Wang et al., 1999). The N-
terminal truncated recombinant human TK2 (MW 28 kDa), corresponding to 
the mature mitochondrial TK2, exhibited indistinguishable kinetic properties 
with the native enzyme. Cloning of full-length mouse TK2 was performed by 
the same group and the open reading frame of the mouse TK2 cDNA contained 
an N-terminal mitochondrial targeting signal, which was proven to be essential 
for the mitochondrial translocation of TK2 (Wang & Eriksson, 2000). The TK2 
gene in human cells exhibits a complex and tissue-specific transcription pattern 
and four different transcripts were identified. Two major transcripts of 4.0 kb 
and 2.2 kb were found in most tissues, while two additional transcripts of 1.35 
kb and 4.0 kb were discovered in proliferating tissues e.g., testis and thymus 
(Wang et al., 1999; Johansson & Karlsson, 1997). 
TK2 is able to phosphorylate many pyrimidine nucleoside analogs, which 
are clinically utilized in anti-viral and anti-tumor therapies. Thymidine 
derivatives with modifications on the sugar moiety such as 3’-azido-2’,3’-
dideoxythymidine (AZT), arabinofuranosyl thymidine (araT) and 3’-fluoro-
2’,3’-dideoxythymidine (FLT) could be phosphorylated by TK2, but at much 
lower rates, while 2’,3’-didehydrodideoxy-thymdine (d4T) was an inert 
substrate for TK2. TK2 showed less than 10% activity with AZT compared 
with that of dThd (Munch-Petersen et al., 1991). In spite of a poor substrate, 
the phosphorylation of AZT by TK2 is important for the pharmacological 
activation of this pro-drug in non-proliferating cells such as macrophages 
(Arner et al., 1992). TK2 can also recognize several dUrd analogs as substrates, 
including 5-fluorodeoxyuridine (FdUrd), 1-(2’-deoxy-2’-fluoro-1-β-D-
arabinofuranosyl)-5-iodouracil (FIAU), 2’,2’-difluoro-deoxyuridine (dFdU), 
and in particular (E)-5-(2-bromovinyl)-2’-dUrd (BvdU). The latter has been 
used to discriminate the activities of TK1 and TK2 in extracts, because BvdU 
is an excellent substrate for TK2, exhibiting very low activity with TK1 (Wang 
& Eriksson, 2008; Wang et al., 1999; Wang & Eriksson, 1996; Eriksson et al., 
1991). TK2 can also interact with several uridine derivatives, such as 5-methyl-
Urd, 5-(2-bromovinyl)-Urd (5-BV-Urd), and 5-iodo-Urd with high affinity 
(Ki/Km of 1-10), but very low catalytic efficacy. Uridine is a very poor 
substrate for TK2 (Balzarini et al., 2000). In addition, TK2 is able to catalyze 20 
the phosphorylation of a number of dCyd analogs such as 2’,2’-difluoro-
deoxycytidine (dFdC) and araC. 
The first extensive kinetic analysis on TK2 was performed in 1990s by 
Munch-Petersen and coworkers with enzyme purified from human leukemic 
spleen. They found that when dCyd and dUrd were substrates, the reactions 
followed normal hyperbolic Michaelis-Menten kinetics, with Km ( μM) and 
Vmax/Km (units/mg/μM) values of 36 and 25 for dCyd, and 6 and 115 for dUrd, 
respectively. In contrast, the phosphorylation of dThd exhibited negative 
cooperativity with Hill coefficients (h or n) in the range of 0.3-0.5. It implies 
that the affinity of dThd to TK2 declined as its concentration increased as 
shown by the biphasic Hofstee plot; the Km value was 0.3 μM, when the dThd 
concentration was below 8 μM, while above this concentration the Km value of 
dThd was 16 μM. AZT phosphorylation was also associated with negative 
cooperativity (Munch-Petersen, 2010; Munch-Petersen et al., 1991). These 
kinetic characterizations were in excellent agreement with the results obtained 
with N-terminally truncated recombinant human TK2 (Wang et al., 1999). 
McKee and coworkers investigated the kinetics of exogenous dThd and 
AZT phosphorylation by intact mouse mitochondria isolated from heart, liver, 
and brain by measuring the overall rate of total phosphorylation. They 
demonstrated that mitochondria isolated from all three tissues were capable of 
transporting dThd into the matrix, which contained all essential enzymes 
including TK2, TMPK, and NDPK, to convert dThd to mono/di/tri-phosphate 
forms. The kinetics of dThd phosphorylation showed apparent negative 
cooperativity, with different catalytic efficiencies. In addition, heart, liver and 
brain mitochondria could also take up AZT from the medium, but were unable 
to phosphorylate it beyond the monophosphate form. It was noteworthy that 
the negative cooperativity of AZT was observed in heart and liver 
mitochondria but not in brain mitochondria. Instead, mitochondria exhibited 
non-cooperativity of AZT phosphorylation and negative cooperativity of dCyd 
phosphorylation (McCann et al., 2012; Susan-Resiga et al., 2007; Lynx & 
McKee, 2006; McKee et al., 2004). The complex and tissue-dependent kinetic 
behavior of TK2 contributes to the difficulties in understanding the regulation 
of this protein in physiological conditions. The mechanism underlying the 
biphasic kinetics of TK2 towards certain substrates is not clarified, which to a 
large extent could be due to the lack of structure information regarding TK2. It 
is unlikely that the TK2 monomer contains multiple substrate binding sites, 
which are supposedly required for cooperative kinetics. Therefore, it was 
suggested that TK2 may exist as a homo-multimer with two conformational 
forms in equilibrium (Radivoyevitch et al., 2011; Munch-Petersen, 2010).  21 
1.2.4  Deoxyguanosine kinase (dGK, E.C. 2.7.1.113) 
dGK (NTP: deoxyguanosine 5’-phosphotransferase), also known as DGUOK, 
is an essential component of the dNTP salvage synthesis pathway in 
mammalian mitochondria and mediates the initial rate-limiting phosphorylation 
of dAdo, dIno and dGuo with ATP as the most efficient phosphate donor, 
while dATP and dGTP are feedback inhibitors. Together with TK2, 
mitochondrial dGK is able to phosphorylate all four deoxynucleosides to 
supply mitochondria with mtDNA building blocks. Similar to TK2, dGK is 
also assumed to be constitutively expressed in most tissues and the levels of 
dGK correlated to the amount of mitochondria (Wang & Eriksson, 2003; 
Eriksson et al., 2002; Arner & Eriksson, 1995).  
Human dGK is encoded by a nearly 32 kb gene (DGUOK) with 7 exons 
localized on chromosome 2q13 and its cDNA codes for a 277 amino acid 
polypeptide with a mitochondrial import signal (17 amino acids) at the N-
terminus. A major 1.35-kb dGK mRNA transcript was reported in most tissues 
by Northern blot analysis, although four other alternative splice variants have 
been described (Mousson de Camaret et al., 2007; Eriksson & Wang, 2002; 
Johansson et al., 1996). The active form of dGK protein is a dimer of two 
identical 30 kDa subunits and normally located in the mitochondrial matrix. 
Mitochondrial dGK, however, was found to relocate to the cytosolic 
compartment at a similar rate as cytochrome c during the course of apoptosis in 
human epithelial kidney (HEK) 293 and human lymphoblast Molt-4 cell lines. 
Although the role of the specific redistribution of dGK is not understood, it 
might contribute to the apoptotic cascade by being involved in the activation of 
apoptotic nucleotide cofactors e.g., dATP (Jullig & Eriksson, 2001).  
Like other dNKs, dGK is able to phosphorylate several cytostatic analogs 
such as 2-chlorodeoxyadenosine, arabinosyl guanine, and 2’,2’-
difluorodeoxyguanosine, which are also substrates for cytosolic dCK due to the 
overlapping substrate specificity between the two kinases (Munch-Petersen & 
Piškur, 2007). Therefore, dGK may play an important role in the activation of 
these nucleoside pro-drugs, particularly in the tissues where dCK activity is 
low. 
1.2.5  The structures of dNKs 
The X-ray crystallographic three-dimensional structures of the human dCK, 
dGK, and TK1 have been solved since 2001 (Figure 2B) (Welin et al., 2004; 
Sabini et al., 2003; Eriksson et al., 2002; Johansson et al., 2001). According to 
the primary sequences, the dNK enzymes could be roughly divided into two 
families: TK1 forms a family of its own, indicating that this enzyme has a 
distinct phylogenetic origin; TK2, dCK, and dGK belong to a homologous 22 
family (the dCK/dGK family), which also includes the dNK in Drosophila 
melanogaster (Dm-dNK). It is noteworthy that Herpes Simplex Virus 1 
thymidine kinase (HSV1-TK) is also considered to belong to the dCK/dGK 
family due to its similar structural folds, although with less than 10% amino 
acid identity (Sandrini & Piskur, 2005; Brown et al., 1995).  
 
Figure 2. (A) Structure model of human TK2 (SwissPort O00142). This model is built with one 
subunit of Dm-dNK (PDB ID: 2VPPB) as the template. The side chains of major amino acid 
residues interacting with deoxynucleoside substrates are shown as sticks (in red) for greater 
clarity. (B) Monomeric structures of human dGK (PDB: 1JAG), dCK (PDB:1P60), TK1 
(PDB:1XBT) and Dm-dNK (PDB:1J90). The α-helices and β-sheets are shown in orange and 
pink, respectively, while the lid region and P-loop (Lasso for TK1) are shown in green and blue, 
respectively. All the figures are plotted with PyMOL. 
As the only deoxyribonucleoside kinase identified in D. melanogaster, Dm-
dNK (NTP: deoxyribonucleoside 5’-phophotransferase, EC 2.7.1.145) is able 
to phosphorylate all four natural deoxyribonucleosides with almost the same 
high turnover numbers and higher efficiencies than those mammalian dNKs 
(Eriksson et al., 2002; Knecht et al., 2002). Dm-dNK has markedly higher 
sequence identity (48%) with TK2, in comparison with dCK/dGK 
(approximately 40%). Therefore its structure is used as the ideal template to 
build structural models of TK2 (Tyynismaa et al., 2012; Perez-Perez et al., 
2008; Perez-Perez et al., 2005). 
As shown in Figure 2, the overall monomer structures of TK2 and other 
dNKs in the same family, have an α/β-architecture where the active site 23 
consists of a five-stranded parallel β-sheet with the strand order β2, β3, β1, β4, 
and β5, all of which are surrounded by nine to ten α-helices (Eriksson et al., 
2002). Interactions between the hydrophobic residues in the α4 and α7 helices 
of each subunit (monomer) form a four-helix bundle at the dimer interface, 
generating the dimer form of dCK, dGK and Dm-dNK. Two sequence motifs 
i.e., the highly conserved P-loop (consensus sequence GX4GKS/T) and the 
arginine-rich lid region with the consensus sequence RX3RXRX2E, play a 
special role in accommodating the phosphate groups of phosphate donors. In 
the structure models of TK2, the P-loop locates at residues Gly57-Ser63, just in 
the turn between β1 and α1. It binds and positions the phosphoryl groups of the 
phosphate donor, while the lid region situated between residues Arg192-
Glu199 is a flexible segment, functioning as a cover for the active site cleft, 
and is critical for ATP binding and catalysis (Figure 2A) (Perez-Perez et al., 
2005). The residues Glu133, Arg134 and Ser135 in TK2 are strictly conserved 
in the dCK/dGK family, form another critical loop (the ERS motif), and play 
an important role in catalysis. In dCK, Glu127 interacts with the magnesium 
ion and Arg128 acts as an anchor to bring the 5’-hydroxyl group of dCyd and 
the γ-phosphate of the phosphoryl donor. Facilitated by the nearby Arg128, 
Glu53 (in the P-loop) in dCK acts as a base in the de-protonation of the sugar 
5’-hydroxyl group (Sabini et al., 2003). The corresponding Glu-Arg pair in 
human TK2 is residues 81 and 134. The substrate binding cleft locates 
perpendicularly to the C-termini of the parallel β sheets of the enzymes. A 
conserved Tyr-Glu pair (TK2, Y99-E201; dNK, Y70-E172; dGK, Y101-E211; 
dCK, Y86-E197) firmly anchors the deoxyribose moiety of the substrate by 
two hydrogen bonds to the 3’-hydroxyl group. The tyrosine hydroxyl group is 
in close proximity to the 2’-sugar position, interfering the binding of 
ribonucleosides (Sabini et al., 2003).  
In TK2, the base moiety of a substrate, such as thymine, is sandwiched 
between the phenyl ring plane of Phe143 by π-π interaction on one side and 
Trp86 as well as Val113 on the other side. Two hydrogen bonds are established 
between residue Gln110 and N3/O4 of the thymine base (Perez-Perez et al., 
2008). The substrate selectivity of different dNKs is considered to be largely 
due to the different amino acid residues located in the plane of the substrate 
binding pocket. Thus, the interaction between a group of substrates and the 
side chain of amino acid in the corresponding position determines the 
discrimination of the dNKs towards different substrates (Sabini et al., 2003; 
Eriksson & Wang, 2002). 24 
1.2.6  Mitochondrial disorders caused by TK2 and dGK mutations 
mtDNA depletion syndrome (MDS) 
Human mtDNA is a 16,569 bp circular double-stranded DNA encoding 13 
polypeptides, which are subunits of mitochondrial respiratory chain complexes, 
i.e., the mitochondrial oxidative phosphorylation system. The nuclear genome 
encodes all the other mitochondrial proteins and peptides (Navarro-Sastre et al., 
2012). Accordingly, an adequate amount of mtDNA and its integrity are 
essential for mitochondrial ATP production, the metabolism of sugar and fatty 
acids, calcium storage and signaling, the regulation of the cellular redox state, 
as well as one part of apoptotic machinery. Energy metabolism predominantly 
relies on cytosolic glycolysis during fetal life and hence functional defects in 
mitochondria usually manifest only after birth (Suomalainen & Isohanni, 2010). 
However, the replication and repair of mtDNA proceed throughout the cell 
cycles and thus demand a continuous and balanced dNTPs supply. Today at 
least 12 among over 200 nuclear genes involved in mtDNA replication and 
mtDNA precursor metabolism, are associated with mitochondrial diseases, 
including TK2, DGUOK, TYMP (thymidine phosphorylase), RRM2B (p53R2), 
SUCLA2 (ADP-forming succinyl CoA ligase beta subunit), SUCLG1 (GDP-
forming succinyl CoA ligase alpha subunit), POLG (DNA polymerase γ), 
POLG2 (accessory subunit of DNA polymerase gamma), PEO1 (or C10orf2, 
Twinkle, mtDNA helicase), SLC25A4  (or ANT1, the adenine nucleotide 
translocator), OPA1, and MPV17 genes (Uusimaa et al., 2013; Copeland, 2008; 
Eriksson & Wang, 2008). During the past two decades, eight to nine of them 
have been identified as the cause of MDS, which is characterized by severe and 
tissue-specific reduction of mtDNA copy number without qualitative defects in 
mtDNA. Originating from early childhood or the neonatal period, fatal MDS is 
one of the most common forms of childhood respiratory chain deficiencies 
with an approximate frequency of 1/10000, affecting skeletal muscle, brain, 
liver or several tissues with a variety of symptoms such as progressive 
myopathy, hepatopathy and encephalopathy (Suomalainen & Isohanni, 2010; 
Wang, 2010).  
Mutations in TK2, RRM2B, and SUCLA2 are predominantly associated with 
myopathic MDS, and defects in DGUOK,  SUCLG1,  POLG,  PEO1, and 
MPV17 are responsible for hepatocerebral forms of MDS, while 
encephalomyopathic MDS originates from TYMP,  RRM2B,  SUCLG1, and 
SUCLA2 deficiencies (El-Hattab & Scaglia, 2013; Navarro-Sastre et al., 2012; 
Suomalainen & Isohanni, 2010; Wang, 2010; Copeland, 2008). Recently, 
mutations in MGME1 ( C20orf72, mitochondrial genome maintenance 
exonuclease 1), encoding a mitochondrial RecB-type exonuclease, were 25 
reported as a cause of a multi-systemic form of MDS (Kornblum et al., 2013). 
Notably, the clinical phenotypes of various forms of MDS are overlapping and 
heterogeneous, and may affect either a specific tissue or a combination of 
several organs. However, some genes involved in MDS are also associated 
with other clinical disorders e.g., Parkinsonism and ataxia. In addition, 
transient mtDNA depletion could result from long-term use of nucleoside 
analogs, which will be described later. 
TK2-related MDS 
Deficiency of TK2 due to genetic mutations is associated with clinically 
heterogeneous myopathic form of MDS. MDS was initially described by 
Moraes  et al. in 1991, and 10 years later the first report assigning TK2 
mutations to MDS was published by Saada and coworkers, who identified two 
missense mutations His90Asn and Ile181Asn in four individuals with 
devastating isolated skeletal myopathy, mtDNA depletion and death at early 
age (Saada et al., 2001; Moraes et al., 1991). Since then, more than 50 
individuals suffering from MDS with both molecularly confirmed diagnosis 
and histological or biochemical analysis have been linked to a variety of 
genetic alternations in the TK2 gene (Chanprasert et al., 2013). In addition to 
myopathy, neurological phenotypes and multi-tissue pathology have been 
discovered recently in patients carrying defect TK2 (Bartesaghi et al., 2010; 
Gotz et al., 2008). Most patients have an uneventful initial phase, but present 
progressive onset of muscle disorders characterized by generalized hypotonia, 
fatigue, proximal muscle weakness, impaired physical stamina, poor feeding, 
respiratory difficulties, and gradual loss of spontaneous activity from birth to 
about 30 months of age (El-Hattab & Scaglia, 2013). Some other symptoms 
less commonly reported include hepatic disorder, facial weakness, bulbar 
weakness, hepatic disorder, cardiomyopathy, kidney tubulopathy, ptosis, 
encephalomyopathy, and dysarthria (Lesko et al., 2010; Zhang et al., 2010; 
Galbiati et al., 2006).  
Until 2012, twenty-eight patients died from respiratory failure at 0.3 to 16 
years of age, while the majority of the living patients still suffer from severe 
respiratory insufficiency (El-Hattab & Scaglia, 2013). Midler forms with 
longer survival and diverse MDS phenotypes caused by TK2 mutations were 
also described, including late onset proximal muscle weakness (Oskoui et al., 
2006), progressive sensory neural hearing loss (Marti et al., 2010), and adult-
onset progressive myopathy (Behin et al., 2012). Therefore, residual TK2 
activity in the tissues affected by MDS is sufficient to support survival. 
Particularly, the severity of the TK2 deficiency is correlated with the 
phenotype in patients, namely, severe impairment of TK2 resulted in 26 
encephalomyopathy whereas partial reduction of TK2 was associated with 
myopathy (Zhou et al., 2013). However, the tissue specific pathogenesis of 
MDS caused by genetic alternations in TK2 as well as other genes remains 
largely unexplained. 
In order to investigate the molecular mechanism of mtDNA depletion due 
to  TK2 mutations and the physiological role of TK2, TK2-deficient mouse 
strains were generated by two groups in 2008 (Akman et al., 2008; Zhou et al., 
2008). It was found that TK2
-/- mice showed growth retardation and died within 
2 to 4 weeks of life with mtDNA depletion in the brain and adipose tissues. 
Immediately after birth progressive reduction of mtDNA in skeletal muscle, 
heart, liver and spleen was observed but without elevated mtDNA mutation 
rates. Pronounced hypothermia and loss of hypodermal fat and abnormal 
brown adipose tissue were also observed (Zhou et al., 2008). The gradual 
hepatic mtDNA depletion was accompanied by increasingly hypertrophic 
mitochondria and accumulation of fat vesicles and affected liver function and 
lipid metabolism (Zhou et al., 2013). In the same TK2-knockout mouse strain, 
the importance of TK2 in neuronal homeostasis was emphasized by the 
findings that after 10-12 days of life these mice had a severe ataxic phenotype 
with histopathological neurodegeneration of cerebellum. Impaired electron 
transport chain complexes and mtDNA depletion (~70% on day 12) in the 
brain were the most likely mechanism (Bartesaghi et al., 2010). Recently, 
Paredes et al. analyzed skeletal muscle and heart muscle isolated from TK2 
negative mouse strain during postnatal development. Compared with those of 
normal mice, the mtDNA levels were depleted in both tissues and the skeletal 
muscles appeared be significantly underdeveloped. In contrast, the heart 
muscle was not apparently affected. Furthermore, primary myoblasts from the 
TK2
-/- mouse strain exhibited slow proliferation and reduced ability to 
differentiate. Hence, they proposed that TK2 deficiency could disturb the 
function of myogenic progenitor cells in postnatal skeletal muscle tissue and 
this might contribute to the abnormal phenotype appearing in the animal model 
(Paredes et al., 2013). On the other hand, a knockin murine model harboring an 
H126N TK2 mutation analogous to human H121N TK2 mutation was 
developed and reported to have negligible TK2 activity in many organs. At day 
10, the TK2
-/- pups exhibited growth deceleration, rapidly developed 
progressive and severe encephalomyelopathy with unbalanced dNTP pools, 
particularly in brain and heart. mtDNA depletion was also found in many 
tissues (Paredes et al., 2013; Dorado et al., 2011; Akman et al., 2008). 27 
dGK-related MDS. 
Deficiency of dGK is associated with hepatocerebral forms of MDS 
(multisystem disorders with pronounced involvement of liver in neonates) and 
hepato-specific diseases in late infancy or childhood (Poulton et al., 2009; 
Mandel et al., 2001). To date, approximately 100 individuals from diverse 
ethnic origins have been reported to suffer from MDS caused by over 40 
distinct mutations in DGUOK. The majority of these individuals manifest liver 
dysfunction with or without accompanying neurologic impairment at birth or 
within the first month of life with subsequent developmental regression, rotary 
nystagmus, and hypotonia (El-Hattab & Scaglia, 2013; Suomalainen & 
Isohanni, 2010; Poulton et al., 2009). Most patients die from progressive 
hepatic dysfunction within the first year of life (Dimmock et al., 2008). It was 
reported that early liver transplant might be helpful to patients who have only 
isolated liver disorders (Mousson de Camaret et al., 2007; Freisinger et al., 
2006).  
TK2 and dGK-related PEO 
In contrast to infantile-onset MDS associated with severe mtDNA depletion, 
progressive external ophthalmoplegia (PEO) is a manifestation of multiple 
mtDNA deletions, which accumulate with age and cause late-onset symptoms 
in post-mitotic tissues such as nervous system and skeletal muscle. PEO is 
caused by mutations in nuclear genes encoding proteins that are involved in 
mtDNA replication and nucleotide metabolisms (Brandon et al., 2013; Zeviani 
et al., 1989). Patients suffering from PEO usually manifest variable clinical 
symptoms including adult-onset weakness of the external eye muscles, bilateral 
ptosis, exercise intolerance, proximal muscle weakness, wasting, hearing loss, 
hypogonadism, optic atrophy and Parkinsonism (Tyynismaa et al., 2009; 
Copeland, 2008). The autosomal dominant form of PEO (adPEO) has been 
associated with mutations in POLG1,  POLG2,  PEO1,  SLC25A4,  RRM2B, 
OPA1 and MFN2 (Rouzier et al., 2012; Tyynismaa et al., 2009; Hudson et al., 
2008; Longley et al., 2006; Spelbrink et al., 2001; Van Goethem et al., 2001; 
Kaukonen et al., 2000). In contrast, the autosomal recessive PEO (arPEO) has 
only been associated with mutations in POLG1 (Van Goethem et al., 2001). In 
2012, Ronchi et al. identified autosomal recessive mutations in the DGUOK 
gene as a novel genetic cause of arPEO by next-generating sequencing of 
known mitochondrial targets (MitoExome) (Ronchi et al., 2012). This was 
previously only associated with the infantile hepatocerebral form of MDS. 
Mutations in TK2 gene have also been reported to cause arPEO (Tyynismaa et 
al., 2012). The overlaps of genetic backgrounds among different forms of 28 
MDS and PEO imply that defects in the same gene might cause strikingly 
diverse manifestations. 
1.3  Nucleoside analogs used in antiretroviral treatment 
Analogs of natural nucleosides play important roles in anti-viral and anti-tumor 
chemotherapy. These synthetic compounds are widely administrated in the 
treatment and prevention against a vast number of viral infections and cancers, 
including but not limited to human immunodeficiency virus (HIV), hepatitis B 
virus (HBV), hepatitis C virus (HCV), leukemia, as well as cancers in skin, 
breast and lung. As the first anti-viral drug, 5-iodo-2’-deoxyuridine (idoxurine) 
was synthesized in 1959 and found to be effective for topical treatment of 
herpes keratitis (De Clercq & Field, 2006; Prusoff, 1959). Since then, several 
nucleoside analogs have been developed and approved for clinical use. 
Particularly, nucleoside analog reverse transcriptase inhibitors (NRTIs) are the 
backbones in highly active antiretroviral therapy (HAART), which is a 
combination of three or more antiretroviral drugs, including NRTIs, 
nonnucleoside analog reverse transcriptase inhibitors (NNRTIs), protease 
inhibitors (PIs), and lately fusion inhibitors. Among anti-HIV agents approved 
during the past decades by FDA, there are 8 NRTIs: the thymidine analogs 
zidovudine (AZT/ZDV) and stavudine (d4T), the deoxycytidine analogs: 
lamivudine (3TC), zalcitabine (ddC) and emtricitabine (FTC), the guanosine 
analog: abacavir (ABC), the adenosine analogs: didanosine (ddI) and tenofovir 
(TDF) which in fact is a nucleotide analog. Due to severe toxicity, ddC is no 
longer marketed (Warnke et al., 2007). In this section, some general 
characteristics of NRTIs are briefly summarized, followed by a description of 
the metabolism of two classical analogs: AZT and ddI. 
1.3.1  General characteristics of NRTIs 
Administered as un-phosphorylated pro-drugs, NRTIs can penetrate into cells 
and be activated by several cellular kinases, eventually leading to the formation 
of the corresponding triphosphates. These are membrane impermeable and 
exert their anti-viral activity. Activation of the purine analogs ddI and ABC 
requires an extra enzymatic deamination step to ddA and carbovir (CBV), 
respectively (Vivet-Boudou et al., 2006; Johnson & Fridland, 1989). Hence, 
the efficiencies of pro-drug activation determine the intracellular levels of 
active NRTIs. Referring to the structural similarities, the NRTI triphosphates 
are capable of competing with the corresponding natural substrates for the 
active site of the viral reverse transcriptase (RT), which catalyzes the synthesis 
of viral DNA using RNA as template. Since the 3’-hydroxyl group of the 29 
pseudo-ribose moiety in NRTI monophosphates is missing, the essential 3’-5’ 
phosphodiester bond cannot be generated. Thus the replication of HIV is 
terminated. In contrast, non-nucleoside analog reverse transcriptase inhibitors 
(NNRTIs) inhibit the RT activity in a non-competitive manner by binding to 
another sites rather than the active site. Accordingly, no phosphorylation is 
required for this type of drugs. 
  NRTIs can suppress HIV replication and delay the acquired immune 
deficiency syndrome (AIDS) progression, and therefore, transform the lethal 
HIV infection into a clinically-tolerable chronic illness. Toxic adverse effects 
of these drugs include cardiomyopathy, encephalopathy, lactic acidosis, hepatic 
steatosis, lipoatrophy, and peripheral neuropathy, which are most likely due to 
mitochondrial dysfunctions similar to the inherited mitochondrial diseases as 
described above (Lund et al., 2007; Kakuda, 2000). Different NRTIs give 
adverse effects in a tissue-specific manner, e.g., AZT affects skeletal muscle 
and causes hematological toxicity and myopathy, while d4T causes 
lipodystrophy and peripheral neuropathy. The lack of correlation between 
structural similarity and tissue-specific side-effect of these analogs implies that 
the metabolism of NRTIs is complex and very likely multiple mechanisms are 
involved in the NRTIs-induced mitochondrial toxicity. 
Another drawback of NRTIs in anti-HIV therapy is the rapid emergence of 
drug resistance that limits the clinical benefits of NRTIs and ultimately leads to 
treatment failure. The pol gene encoding HIV RT, which is the target of NRTIs, 
has a high mutation rate because the reverse transcriptase is error-prone (Vivet-
Boudou et al., 2006). In addition, the increased mutation rate of NRTI-resistant 
RT contributes to emergency of drug resistant viruses (Jewell et al., 2003). 
1.3.2 3’-azido-2’,3’-dideoxythymidine  (AZT) 
Discovery and clinic application 
AZT (zidovudine, ZDV, Retrovir
®, IUPAC: 1-[(2R,4S,5S)-4-azido-5-
(hydroxymethyl) oxolan-2-yl]-5-methyl-pyrimidine-2,4,-dione) was originally 
synthesized in 1964 as a potential anti-cancer agent (Horwitz et al., 1964). 
AZT was found to be able to inhibit the replication of the retrovirus which 
leads to AIDS (Mitsuya et al., 1985). Since then, application of AZT has 
delayed disease progression in HIV-infected individuals and prolonged 
survival in patients with AIDS. In the United States, AZT has protected more 
than one thousand children every year by significantly suppressing the mother-
to-child transmission of HIV (Poirier et al., 2003). 30 
The metabolism of AZT 
Prior to intracellular activation, cellular uptake across plasma membrane is the 
initial step of pharmacological action of NRTIs, including AZT. Different from 
most nucleosides, AZT was found to permeate cell membranes as well as the 
blood-brain barrier and the blood-placenta barrier by passive diffusion, partly 
due to the lipophilic nature of the azido group (D'Andrea et al., 2008; Dancis et 
al., 1993; Zimmerman et al., 1987). AZT is a substrate for a variety of 
nucleoside transporters, i.e., CNT1, CNT3, and ENT2, belonging to 
concentrative and equilibrative nucleoside transport protein families (CNT and 
ENT, respectively) (Errasti-Murugarren & Pastor-Anglada, 2010; Purcet et al., 
2006; Pastor-Anglada et al., 2005). Once inside cells, AZT is phosphorylated 
by three successive steps to AZT-TP. HIV does not encode any nucleoside 
kinase, thus the activation of AZT and other NRTIs completely relies on host 
cell enzymes: TK1 and TK2 catalyze the first phosphorylation of AZT to AZT-
MP, which could be further phosphorylated by TMPK to AZT-DP (Cihlar & 
Ray, 2010; Van Rompay et al., 2000; Arner & Eriksson, 1995). The final 
phosphate group is added to AZT-DP by NDPK to generate AZT-TP (Krishnan 
et al., 2002). The bottleneck in AZT activation is the second phosphorylation 
step catalyzed by TMPK rather than the first reaction which usually limits the 
activation of other nucleoside analogs (Lavie et al., 1997). Meanwhile, most 
enzymes involved in AZT activation are active in all cell cycle phases, whereas 
TK1 is down-regulated in resting cells. Consequently, AZT preferentially 
exerts anti-viral activity in proliferating cells like lymphoblasts (Gao et al., 
1993). 
Adverse effects associated with AZT 
In early clinical chemotherapy against HIV, AZT was administrated alone in 
relatively high concentrations and often resulted in severe mitochondrial 
dysfunction, limiting its clinical effectiveness (Dalakas et al., 1990). Although 
the doses of AZT are much lower in the modern HAART regime, long-term 
exposure to this analog still causes adverse effects including anemia, lactic 
acidosis, neutropenia, skeletal muscle myopathy, and cardiomyopathy with 
mtDNA depletion (Scruggs & Dirks Naylor, 2008; Samuels, 2006). All of 
these side effects were attributed to AZT-mediated mitochondrial toxicity, 
which was believed to be a class-wide major adverse effect associated with 
NRTIs (Warnke et al., 2007). Early studies focused on defective mtDNA 
replication in cells with AZT-induced side effects. The AZT toxicity was 
ascribed to the inhibition of mtDNA polymerase-γ,  i.e., the DNA pol-γ 
hypothesis, which states that AZT-TP inhibits DNA pol-γ by incorporation 
(Lewis & Dalakas, 1995; Lewis et al., 1994). AZT-MP acts as a chain 31 
terminator because it lacks the 3’-OH group and it cannot be removed 
efficiently by the 3’-5’ proofreading exonuclease of mtDNA polymerase (Lee 
et al., 2003).  
Accumulating experimental evidences indicated that the inhibition of DNA 
pol-γ by many anti-viral NRTIs, such as ddC, ddI and d4T, was a primary 
factor involved in the NRTI-related mitochondrial toxicity, since the active 
forms of these analogs were found to be strong inhibitors of pol-γ. Furthermore, 
the strength of the interactions with pol-γ correlated with their mitochondrial 
toxicity (Bienstock & Copeland, 2004; Lewis et al., 2003). However, AZT 
seemed to be an exception. As a poor pol-γ inhibitor, this thymidine analog 
showed unexpectedly high mitochondrial toxicity. Hanes et al. found that at 
least 100 μM AZT-TP was required to reach 50% inhibition of pol-γ, whereas 
the intracellular AZT-TP level was far too low to explain the mitochondrial 
toxicity (McCann et al., 2012; Hanes & Johnson, 2007; Lynx et al., 2006; 
McKee et al., 2004; Lee et al., 2003).  
An alternative mechanism underlying the AZT-associated mitochondrial 
toxicity has been suggested to be the inhibition of TK2 and induction of 
oxidative stress as described below. 
AZT is a potent inhibitor of the dThd phosphorylation catalyzed by TK2 
and inhibition of TK2 activity could result in a depleted mitochondrial dTTP 
pool which limits mtDNA replication and ultimately leads to mtDNA depletion 
(Susan-Resiga et al., 2007; Lynx et al., 2006). Compared with proliferating 
tissues, most post mitotic tissues mainly rely on the TK2-catalyzed dThd 
phosphorylation for the maintenance of dTTP pool and therefore exhibit higher 
sensitivity to AZT. Altered dTTP pool (>50% reduction) has been confirmed in 
perfused rat heart with short-term AZT exposure (Morris et al., 2009). These 
manifestations are similar to those found in patients suffering from TK2 
deficiency as described in the previous sections. Thus these facts strongly 
imply that the inhibition of intramitochondrial dThd phosphorylation exerted 
by TK2 contributes to the mitochondrial toxicity of AZT and other related 
NRTI drugs. 
To release and revert mt toxicity related to AZT and other NRTIs, uridine 
supplementation has been tested both in vitro and in clinical trials. Uridine can 
fully abrogate the side effects of AZT and other pyrimidine NRTIs analogs and 
normalize cell function and mtDNA levels in human HepG2-hepatocytes, bone 
marrow progenitor cells and HIV-infected peripheral blood mononuclear cells 
(Walker & Venhoff, 2005; Walker et al., 2003; Sommadossi et al., 1988). In 
mice, oral uridine administration was able to antagonize the AZT-induced 
myopathy, peripheral neuropathy, and encephalopathy (Venhoff et al., 2010; 
Lebrecht et al., 2008). Banasch et al. investigated the short-course metabolic 32 
effects of uridine supplementation on lipoatrophic HIV-infected individuals 
receiving dThd analog drugs and found that the uridine-enriched food, 
NucleomaxX, appeared to increase hepatic mitochondrial function (Banasch et 
al., 2006). Oral uridine supplementation could also significantly increase limb 
fat mass during HAART therapy in HIV-patients (Sutinen et al., 2007). The 
exact mechanism underlying the effect of uridine on AZT toxicity is not 
understood. Uridine supplementation could possibly enhance the synthesis of 
thymidine nucleotides and thus help replenish the depleted dTTP pool 
(Lebrecht et al., 2008; Walker & Venhoff, 2005).  
1.3.3 2’,3’-dideoxyinosine  (ddI) 
As the second FDA-approved drug against HIV, ddI (2’,3’-dideoxyinosine, 
DDI, didanosine, Videx
® EC, IUPAC: 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-
yl]-6,9-dihydro-3H-purin-6-one) is administrated in combination with other 
NRTIs in the HAART regimen. ddI is a selective and potent drug against HIV 
in human lymphoid cells and monocytes/macrophages. It is able to raise the 
circulating CD4
+ T cells and decrease plasma HIV RNA levels in HIV-infected 
patients (Yarchoan et al., 1989; Mitsuya & Broder, 1986). Similar to other 
nucleoside drugs, ddI is administrated orally as a pro-drug and demands 
multiple intracellular phosphorylation steps to exert anti-HIV activity. ddI is 
unstable in acidic environments and thus could be easily degraded in the 
stomach, whereas the new enteric-coated capsule formulation of the drug has 
improved its bioavailability (Barreiro et al., 2004). Gibbs et al. showed that ddI 
could cross the blood-brain barriers but had much lower efficiency compared 
to AZT, leading to poor uptake into the central nervous system (CNS)   
(Varatharajan & Thomas, 2009; Gibbs et al., 2003).  
The metabolism of ddI within target cells 
The activation of ddI has an unusual initial step since it is phosphorylated by 
the cytosolic 5’-nucleotidase, cN2, producing ddI monophosphate (ddI-MP). 
This nucleotide is subsequently converted to dideoxyadenosine monophosphate 
(ddA-MP) by adenylosuccinate synthetase and adenylosuccinate lyase. The 
anti-viral active moiety of ddI, ddA-TP is generated by successively adding the 
second and third phosphates to ddA-MP by AMPK and NDPK, respectively 
(Ahluwalia et al., 1993; Franssen et al., 1992). Due to a longer intracellular 
half-life than AZTTP, ddA-TP is able to compete with dATP and thus 
terminate viral DNA replication (Pruvost et al., 2005). ddA was also tested, but 
was found to be metabolized rapidly to ddI (Hartman et al., 1990). ddI can be 
degraded to hypoxanthine and uric acid by PNP and xanthine oxidase, 
respectively. PNP is expressed in most mammalian tissues such as endothelial 33 
cells of blood-brain barrier, intestinal epithelium and erythrocytes at high 
levels. Thus this enzyme could be responsible for most of the intracellular 
elimination of ddI (Singhal et al., 1998). In human blood, the catabolism of ddI 
was found to be extensive and this might explain the short half-life of ddI in 
patients receiving this drug (Back et al., 1992). 
Side effects associated with ddI 
Adverse effects caused by ddI are primarily peripheral neuropathy, lactic 
acidosis, pancreatitis, non-cirrhotic portal hypertension, and retinal toxicity 
(Gabrielian et al., 2013; Chang et al., 2012). The presence of ddI results in 
time- and dose-dependent mtDNA depletion, cell growth inhibition, and 
elevation of intracellular lactate and lipids in cultured HepG2 cells, CEM cells, 
human muscle cells, and healthy primary human T lymphocytes (Setzer et al., 
2005; Lewis et al., 2001; Benbrik et al., 1997). These ddI-induced side effects 
are regarded to be due to mitochondrial toxicity via inhibition of mtDNA 
polymerase γ, i.e., the DNA pol-γ hypothesis (Warnke et al., 2007; Lee et al., 
2003).  
1.4  Protein oxidation and removal of oxidatively damaged 
proteins 
In organism, chemically reactive molecules such as free radicals and related 
oxygen/nitrogen containing species are generated during aerobic metabolism, 
aging, and pathophysiological states. Generally, when the production of 
reactive molecules exceeds their catabolism a state of oxidative stress exists. 
Pro-oxidants are able to react with various biomolecules, which include lipids, 
carbohydrates, nucleotides, and proteins, causing a number of adverse 
alternations e.g., loss of enzyme activity and mutagenesis. On the other hand, 
many of these reactive molecules have been recognized to perform important 
physiological functions during normal metabolisms, including cellular 
signaling, proper development and proliferation. In this section, the effects of 
reactive species derived from oxygen will be described. Attention will be 
mainly focused on the reactive species-mediated protein modifications, 
particularly S-glutathionylation, which has been widely recognized as one of 
the most important protein post-translational modifications. Cells employ a 
variety of defense mechanisms including antioxidants and intracellular protein 
degradation pathways to minimize the deleterious effects of reactive molecules 
and prevent the accumulation of damaged proteins. Therefore, cellular 
antioxidants and protein degradation pathways will also be described. 34 
1.4.1 ROS  and  RNS 
Free radicals, such as superoxide anion radicals (O2•
-), are molecules or 
molecular fragments with odd (unpaired) valence electrons in the outer orbitals 
and they are very reactive towards other substances, including themselves 
(Valko et al., 2007). Together with reactive nitrogen species (RNS), oxygen-
free radicals, also called reactive oxygen species (ROS), are produced in 
normal cellular metabolism and represent the most significant classes of 
radicals generated in living systems. Although without unpaired electrons, 
hydrogen peroxide (H2O2) and singlet oxygen (O2) are still ascribed to ROS. 
Studies on free radicals in biological system date from the 1950s when oxygen 
toxicities were found to be associated with the formation of oxidizing free 
radicals (Gerschman et al., 1954). Since then, the effects of ROS/RNS in 
biological system have been widely studied.  
1.4.2 Sources  of  ROS 
Exogenous ROS can be caused by ultraviolet exposure, radiation, heat stress, 
smoking, excessive exercises, infections, xenobiotics, and drugs (Marchetti et 
al., 2012). In mammalian cells, ROS is produced during normal cellular 
metabolism in various intracellular compartments such as mitochondria. 
Primary endogenous ROS sources include the mitochondrial respiratory chain, 
oxidases in peroxisomes, NAD(P)H oxidase (NOX) isoenzymes, cytochrome 
P450s, the flavoenzyme ERO1 in the endoplasmic reticulum, xanthine oxidase, 
and nitric oxide synthases (Nathan & Cunningham-Bussel, 2013; Kregel & 
Zhang, 2007).  
In eukaryotic cells, mitochondrial ATP production is the most important 
source of ROS (Cadenas & Sies, 1998). During electron transport in aerobic 
respiration, single electrons leak to molecular oxygen (O2) which is reduced to 
O2•
-. This superoxide product is further converted to other ROS including 
H2O2 and hydroxyl radicals (•OH) (Chance et al., 1979). Based on studies with 
electron transport inhibitors, eight sites in mitochondria have been identified to 
generate O2•
-, although the detailed mechanism is still unclear (Sena & 
Chandel, 2012; Brand, 2010). 
Despite of its lower reactivity, H2O2 generated by either endogenous or 
exogenous routes has a longer half-life than other ROS. Therefore, it can 
diffuse through the mt membranes and contribute to cytoplasmic oxidative 
stress. Especially in the presence of transit metal ions, such as Fe
2+ and Cu
+, 
H2O2 can be converted to •OH, which is highly reactive via the Fenton reaction 
(Valko et al., 2007).  35 
1.4.3  Beneficial effects of ROS 
At low or moderate concentrations, ROS/RNS play beneficial roles in various 
processes, including inter-/intracellular signaling and defence against 
infectious agents. For instance, nitric oxide (NO•), which is produced by 
specific nitric oxide synthases (NOSs) in vivo, is an abundant membrane-
permeable small molecule affecting vascular pressure, neuronal transmission, 
immune regulation and many other physiological processes (Hancock et al., 
2001; Bergendi et al., 1999; Chiueh, 1999). Therefore, NO• was appointed as 
the molecule of the year in 1992 (Koshland, 1992).  
1.4.4  Intracellular targets of ROS 
Oxidative stress is the harmful effect of ROS (nitrosative stress in the case of 
RNS) on lipids, nucleic acids and proteins. It takes place when ROS is 
overproduced and/or enzymatic and non-enzymatic antioxidants are deficient. 
Thus, oxidative stress can be defined as an imbalance between ROS production 
and degradation. It is known that oxidative stress is correlated with the normal 
aging process and many severe diseases, e.g., type-2 diabetes mellitus, 
cardiovascular diseases, Alzheimer’s disease, and cancers. It is clear that mt 
disorders contribute, at least in part, to elevated free radical formation (Johns, 
1995). 
Lipid peroxidation 
One of the cellular ROS targets is the polyunsaturated fatty acid of 
phospholipids, which can be oxidized by protonated superoxide anions (HOO•) 
and •OH into polar lipid hydroperoxides through autocatalytic lipid 
peroxidation. The presence of transition metals, like cadmium, accelerates the 
reaction. As a result, ROS increases the fluidity and permeability of the 
damaged membranes and affects the viability of cells or organelles by 
triggering signaling pathways (Avery, 2011). 
ROS induced DNA damage 
ROS can also generate DNA lesions, which include purine/pyridine oxidative 
damage, apurinic/apyrimidinic sites and DNA strand(s) breaks. mtDNA suffers 
from higher levels of oxidative damage than nDNA, due to its localization and 
the less repair capacity of mtDNA pol-γ. Among the bases, guanine is most 
susceptible and can be oxidized by •OH into 8-oxo-7,8-dihydroguanine (8-oxo-
dG), which is very stable and abundant (one 8-oxo-dG per million nucleotides) 
and thus often used as an oxidative stress marker (Kryston et al., 2011). During 
DNA replication, 8-oxo-dG causes GC to TA transversions since dATP can be 36 
incorporated opposite to where the lesion occurs. Unrepaired DNA lesions 
generate mutations and may ultimately lead to cell death.  
Protein oxidation 
Effects of oxidative stress on protein function and structure are very diverse. 
Different proteins have distinct sensitivities to ROS, depending on the 
localization and abundance within cells, the number of redox-sensitive amino 
acids and metal-binding sites, the conformation and turnover rate. Proteins are 
more ROS-sensitive when they are newly synthesized and the length of the 
protein and its amino acid composition are also crucial (Avery, 2011). 
The protein backbone can be oxidized by •OH on the α-hydrogen atom, 
ultimately resulting in protein fragmentation and cross-linkage to other proteins 
(Berlett & Stadtman, 1997). The alternations induced by oxidative stress in 
amino acid residues might be reversible e.g., S-glutathionylation or irreversible 
such as protein carbonylation, depending on the characteristics of the side 
chains. Although oxidation of side chain may occur to almost all amino acid 
residues, sulfur-containing amino acids, cysteine (Cys) and methionine (Met) 
are particularly vulnerable to various ROS and their oxidation is usually 
reversible, generating cysteine mixed disulphides and methionine sulfoxide 
(MetO), respectively. The oxidized products can be reduced via enzymatic or 
non-enzymatic mechanisms. Therefore, cyclic oxidation-reduction of these two 
amino acid residues plays an important role in the protection and regulation of 
cellular proteins. 
Cysteine oxidation and S-glutathionylation 
Cysteine residues are susceptible to oxidative modification due to the reactive 
thiol group. Those cysteine residues on protein surfaces play important roles in 
protein defence against oxidative damage and redox homeostasis. Requejo et al. 
reported that the concentration of exposed protein thiols in mitochondrial 
matrix was 60-90 mM and approximately 26-fold higher than the 
mitochondrial GSH concentration (Requejo et al., 2010). The cysteine residues 
in the active sites of enzymes like glutaredoxin (Grx) detoxify ROS/RNS and 
reduce other oxidized protein thiols. The pKa value of sulfhydryl (-SH) of free 
cysteine is 8.3, which is higher than the physiological pH value 7.4 of normal 
cells. Therefore many cysteine residues exist in protonated forms and will not 
react with oxidants spontaneously under normal conditions. However, the pKa 
value of the -SH group of a protein cysteine is also dependent on its vicinal 
amino acids. For instance, the presence of basic amino acid residues e.g., 
histidine (His) around cysteine residue could lower the pKa value and convert 
the thiol group to redox reactive thiolate anion (Dalle-Donne et al., 2007). 37 
High ROS levels leads to protein cysteinyl residue (PSH) oxidation, generating 
sulphenic acid (PSOH), which is a labile intermediate. PSOH is readily 
reduced back or oxidized into sulphinic acid (PSO2H) and irreversibly into 
sulphonic acid (PSO3H). For some proteins, formation of transient PSOH in 
specific cysteine residue is also essential to generate proper intracellular 
disulfide bonds during folding. 
Alternatively, oxidation of cysteine residues leads to the formation of 
disulfide bonds between PSHs (intra/intermolecular disulfide bonds, 
PSSP/PSSP) or between PSH and the thiol group of low molecular weight 
molecules  e.g., cysteine (S-cysteinylation), GSH and GSSG (S-
glutathionylation). Protein S-glutathionylation is a reversible posttranslational 
modification in which one GSH is added to the protein specific cysteine 
residue. Since free GSH is the predominant intracellular low molecular weight 
thiol-containing molecule, S-glutathionylated proteins are the primary 
intracellular mixed disulfides, while the extracellular proteins like albumin are 
mainly S-cysteinylated due to the abundance of free cysteine in plasma. 
Although the exact mechanism of protein S-glutathionylation has not been 
resolved, some mechanisms of glutathionylation have been described (Cooper 
et al., 2011; Dalle-Donne et al., 2009; Mieyal et al., 2008). As illustrated in 
Figure 3, proteins S-glutathionylation can occur via (i) thiol-disulfide exchange 
between PSH and GSSG. This exchange reaction is unfavorable due to the high 
intracellular GSH/GSSG ratio. However, some proteins, such as c-Jun, have 
unusually high thiol redox potential and thus could be glutathionylated by 
GSSG (Klatt et al., 1999). Under severe oxidative stress, the GSH/GSSG ratio 
can decrease drastically, and approximately half of PSH could be converted 
into PSSG if the GSH/GSSG ratio declined to 1 (Gilbert, 1990). In 
mitochondria, the physiological pH is around 8, which is close to the pKa value 
of PSH. As a result, the thiol-disulfide exchange triggered by GSSG can be 
facilitated in the mt matrix (Hurd et al., 2005). This is the only pathway 
requiring GSSG accumulation. (ii) thiyl radical intermediates interactions, i.e., 
PS• and GS• produced by one-electron oxidation of PSH and GSH form 
mixed disulfide bond by radical recombination. In the presence of oxygen, PS• 
and GS• can also react with GSH and PSH, respectively, leading to the 
formation of PSSG and a superoxide radical. (iii) sulfenic acid intermediates. 
PSOH is an early intermediate during PSH oxidation and glutathionylation 
may readily occur between PSOH and GSH and subsequently produce PSSG 
and H2O. Therefore, this protein post-translational modification is important to 
prevent PSOH from further detrimental oxidation to PSO2H or PSO3H. (iv) 
induction by nitric oxide (NO). Nitrosative stress or in the presence of NO, 
PSH and GSH can be converted to PSNO and GSNO, respectively. These 38 
products are reactive towards thiol groups. Consequently, glutathionylated 
protein is generated by reactions between PSH and GSNO or between PSNO 
and GSH. The ease of protein S-glutathionylation is influenced by factors 
similar to those affecting protein cysteine residue oxidation, e.g., location and 
accessibility, the pKa value of the –SH group, vicinal amino acids, and divalent 
cations. Furthermore, the GSH/GSSG ratio determines the equilibrium of the 
reversible protein S-glutathionylation reaction.  
 
Figure 3. Potential mechanisms of protein S-glutathionylation. The protein S-glutathionylation 
could occur via (i) thiol-disulfide exchange between P-SH and GSSG; (ii) thiyl radical 
intermediates; (iii) sulfenic acid intermediates; (iv) induction by nitric oxide. 
Protein S-glutathionylation is fully reversible and de-glutathionylation is 
catalyzed specifically and efficiently by Grx in mammalian cells, but not by 
other thiol-disulfide oxidoreductase like thioredoxin (Chrestensen et al., 2000). 
Grx promotes the reduction of PSSG, since it has unique cysteine thiol groups 
(pKa=3.5) in the active site. These can react with PSSG to form a relatively 
stable catalytic S-glutathionyl intermediate (Grx-SSG), which can be reduced 
by GSH to Grx and GSSG (Peltoniemi et al., 2006). Starke et al. demonstrated 
that Grx also catalyzes protein S-glutathionylation in the presence of the GS-
thiyl radical generating systems (Fe
2+-ADP/H2O2+GSH or HRP/H2O2+GSH) 
(Starke et al., 2003). 39 
1.4.5 Antioxidants 
In order to minimize the effects of high ROS, antioxidant enzymes e.g., 
superoxide dismutases (SODs), catalase (CAT) and glutathione peroxidase 
(GPx), and non-enzymatic antioxidants such as glutathione (GSH) and vitamin 
E, are employed as one of the most crucial defence mechanisms. It is essential 
for organisms to maintain a balance between ROS production and their 
scavenging by antioxidants. 
Glutathione 
In nearly all prokaryotic and eukaryotic cells, except some gram-positive 
bacteria, tripeptide glutathione (GSH, γ-L-glutamyl-L-cysteinyl-glycine) is the 
most abundant intracellular low-molecular-mass non-protein thiol containing 
antioxidant. It exists in two forms, reduced GSH (MW 307.33) and oxidized 
GSSG (MW 612.63). The special peptide bond formed by the γ-carboxyl group 
ensures relative high stability of GSH against cellular peptidases. Glutathione 
disulfide (GSSG), is the main oxidation product of glutathione and could be 
reduced back to GSH in response to diminished oxidative stress spontaneously 
or catalyzed by GSSG reductase. Accordingly, the ratio of the redox couple 
GSH/GSSG is an indicator of intracellular redox status. In contrast to the low 
concentration in plasma (10-30 μM in human), the intracellular GSH level is 
generally in the millimolar range (0.2-15 mM) and GSH/GSSG ratio within 
cells is more than 100:1, but they vary among different types of cells and 
various subcellular compartments. For instance, in the cytosol, nuclei and 
mitochondria, GSH is predominantly in the reduced form, while in the 
endoplasmic reticulum (ER) the GSH/GSSG ratio ranges from 1:1 to 3:1 
(Hwang et al., 1992). Brain cells have lower GSH concentration (1-3 mM) than 
non-nervous cells (1-10 mM), thus is more susceptible to ROS/RNS. The GSH 
concentration is highest in liver and kidney, in particular in the liver, which 
determines the glutathione level in plasma (Purucker et al., 1995). 
The GSH and GSSG couple is also present extracellularly but at low 
concentrations, approximately 2.8 μM and 0.14 μM, respectively. In contrast, 
free cysteine (Cys) and cystine (CySS) are the major extracellular low 
molecular weight thiol/disulfide redox couple, with predominantly cystine 
(>40 μM) compared to cysteine (8-10 μM) (Banerjee, 2012). Accordingly, the 
extracellular compartment is in a more oxidized redox status compared with 
that inside cells. 
Enzymatic antioxidants 
In addition to non-enzymatic antioxidants, organisms can benefit from an 
enzymatic strategy to keep redox homeostasis, e.g., by modulation of the 40 
steady-state concentrations of peroxides and lower energetic cost. Since 
enzymes can be regulated at multiple levels, e.g., transcription, translation and 
posttranslation, these catalytic antioxidants can be induced, activated or 
inhibited under distinct conditions to regulate the levels of ROS/RNS. The 
most efficient enzymatic antioxidants are superoxide dismutase (SOD), 
catalase (CAT) and glutathione peroxidase (GPx). 
Superoxide dismutase (EC 1.15.1.1) catalyzes the one-electron dismutation 
of primary ROS superoxide into less reactive hydrogen peroxide and oxygen. 
Therefore SOD protects cells from the damage caused by superoxide and its 
more aggressive derivatives. In human cells, three different SOD isoforms 
have been discovered in different compartments, i.e., Cu/Zn-SOD/SOD1 in 
cytosol and mitochondrial intermembrane space, mitochondrial Mn-
SOD/SOD2, and extracellular (EC)-SOD3 (Valko et al., 2007). 
Hydrogen peroxide generated by SODs or other metabolic pathways is 
further detoxified into water and oxygen by the heme-containing catalase (EC 
1.11.1.6), an enzyme found in almost all aerobic organisms. Mammalian 
catalase is considered to be located mainly in the peroxisomes and usually 
exists as a homotetramer (~240 kDa) with NADPH bound as a protector 
(Kirkman & Gaetani, 2007).  
Glutathione peroxidase (GPx, EC 1.11.1.19) is a general name for a family 
of phylogenetically related enzymes, which catalyze the reduction of hydrogen 
peroxide and organic peroxides into water and alcohols, respectively, using 
GSH as an electron donor. In humans, eight different isoforms of GPx have 
been identified in different intra/extracellular locations. GPx1-4 as well as 
GPx6 contain selenocysteine (Sec) residue at the active center, which is 
essential for catalysis (Brigelius-Flohe & Maiorino, 2013).  
There are some other reductases and non-enzymatic antioxidants in cells 
balancing the redox milieu, such as thioredoxin and thioredoxin reductase. This 
topic is beyond the scope of this thesis and therefore, will not be discussed 
further. 
1.4.6 AZT-mediated  oxidative  stress 
Nucleoside analogs like AZT, d4T, ddI, and 3TC are as mentioned potent 
antiretroviral drugs and some of them are still used in anti-HIV therapy. In this 
section, recent evidence for the involvement of ROS as an important cause for 
the severe adverse effects associated with the clinical use of nucleoside analogs 
will be described. 
The oxidative stress caused by AZT is well studied in animal models, 
cultured cells, and also patients during AZT treatment. At the beginning of 
1990s, Hayakawa et al. found that AZT caused dose-dependent increase of 8-41 
oxo-dG in mouse liver mtDNA and proposed that the oxidative damage of 
mtDNA was the major cause of AZT-associated mitochondrial myopathy 
(Hayakawa et al., 1991). Viña and coworkers reported that mice administrated 
with AZT had higher levels of mitochondrial 8-oxo-dG, lipoperoxidation, and 
GSH oxidation in skeletal muscle, liver and heart. Supplementation with 
vitamins C and vitamins E could prevent and reverse the AZT-caused oxidative 
damage. They also demonstrated that HIV-infected individuals receiving AZT 
treatment had much higher 8-oxo-dG level in the urine than healthy individuals 
and HIV-positive untreated patients (de la Asuncion et al., 2004; de la 
Asuncion et al., 1999; de la Asuncion et al., 1998). Instead of depleting 
mtDNA, short-term (2 weeks) exposure of growing rats to AZT led to ROS 
and peroxynitrite production and subsequent single-strand DNA break, lipid 
peroxidation, and protein carbonylation in rat cardiac muscle mitochondria. It 
was suggested that the AZT-triggered ROS were important factors in the AZT-
associated myopathy and cardiomyopathy prior to mtDNA damage (Szabados 
et al., 1999). Oxidative stress has also been observed in cultured human 
placental cell, adipocytes, macrophages, HepG2, and fibroblasts receiving AZT 
treatment (Caron et al., 2008; Lund et al., 2007). It is noteworthy that the effect 
of AZT on intracellular ROS generation is enhanced in the absence of serum. 
Actually, in most investigations, including those mentioned above, the 
intracellular/mitochondrial reactive species were determined by indirect ROS 
detection methods, e.g., GSH/GSSG level, carbonylated protein products, 8-
oxo-dG, and fluorescent redox indicators like CM-H2DCFDA. Real-time 
measurement of reactive species in single macrophage cell was done by Woo 
and coworker in 2010. They used electroanalytical techniques, which identify 
and quantify various electroactive species as efficiently as 1000 molecules per 
millisecond to analyze the pro-oxidative properties of the azido moiety 
electrochemically with microelectrodes by pretreating the cells with AZT and 
its structural isomer 5’-azido-5’-deoxythymidine (5’-AZT). It was shown that 
both AZT and 5’-AZT stimulated the production of O2•
-, NO• and their 
reactive derivatives. The oxidative and nitrosative properties of these two 
thymidine analogs were due to the presence of the azido moiety because the 
pro-oxidative activities were lost when the azide group was blocked (Amatore 
et al., 2010). These results strongly suggest that the oxidative toxicity of AZT 
is independent on the inhibition of mtDNA polymerase-γ, since 5’-AZT cannot 
be phosphorylated to mono/di/triphosphates because it lacks a hydroxyl group 
in the 5’ position.  
As a vital part of the mitochondrial antioxidant defense system, 
mitochondrial Mn-SOD activity was suppressed nearly 60% by AZT in mice 
liver, whereas cytosolic Cu/Zn-SOD was much less affected (Prakash et al., 42 
1997). Azidyl radicals were generated from azido-containing inorganic/organic 
molecules (Komarov et al., 2004). Passarella et al. demonstrated that the 
addition of AZT to isolated rat heart mitochondria stimulated the generation of 
superoxide anions in a concentration-dependent manner, in particular when 
mitochondrial oxygen consumption was inhibited (Valenti et al., 2002). 
All these results suggest that AZT can promote ROS generation and induce 
oxidative stress in mitochondria, at least in part, due to the pro-oxidative nature 
of the azido moiety. During long-term administration AZT-triggered ROS 
production may lead to deleterious alternation in mitochondrial membrane 
potentials, electron-transport chain, oxidative phosphorylation, mtDNA 
replication, etc.  
Other nucleoside analogs such as ddI, ddC and d4T were also reported to 
induce oxidative stress in cultivated cells or tissues (Caron et al., 2008; Opii et 
al., 2007; Ferraresi et al., 2006). However, the mechanisms underlying the 
ROS production induced by these analogs is still not resolved (Day & Lewis, 
2004).  
1.4.7  Intracellular protein degradation pathways 
Most proteins in cells are constantly being synthesized and degraded to 
maintain moderate protein turnover rates. Different from other macromolecules 
like DNA, little (if any) precise mechanism has been identified in organisms to 
repair or rescue damaged proteins, in particular those modified/damaged 
irreversibly. It is well-known that the elevation and accumulation of abnormal 
proteins are associated with many diseases. Therefore, the removal of 
misfolded and damaged proteins is as essential as protein synthesis to maintain 
protein homeostasis and the integrity of cellular metabolism. In animal cells, 
two major protein degradation pathways have been identified in the cytosol, 
namely the proteasome and lysosome pathways. In mitochondria several 
different proteolytic strategies are employed to control mitochondrial protein 
quality.  
Lysosome and proteasome 
The lysosomal degradation pathway is mainly responsible for the turnover of 
intracellular materials by autophagy such as mitophagy, and the catabolism of 
alien components like pathogens captured by endocytosis or phagocytosis 
(Boya, 2012; Saftig & Klumperman, 2009). However, most cytosolic 
endogenous protein degradations occur via the ubiquitin-proteasome system in 
eukaryotic cells. Proteins to be degraded are tagged covalently by the 
conserved ubiquitin polypeptide via three consecutive catalytic reactions of 
which the initial one requires ATP. The proteasome complex is able to degrade 43 
proteins and peptides conjugated with polyubiquitin chains in an ATP-
independent manner (Clague & Urbe, 2010; Sorokin et al., 2009). The short 
oligopeptide products are then further degraded by various peptidases to single 
amino acids with expenditure of ATP. Thus, proteasomes play a very important 
role in intracellular protein homeostasis (Sitte et al., 1998). 
Recently, it has been shown that the cytosolic ubiquitin-dependent 
proteasome pathway is also involved in the degradation of some mitochondrial 
proteins. The majority of the mitochondrial proteins (~1500 in humans) are 
encoded by nuclear genes and among them over 100 proteins carrying out 
diverse functions can be ubiquitinated as shown by proteomic studies (Jeon et 
al., 2007). 
Mitochondrial proteolytic systems are composed of three classes of 
proteases, namely processing peptidases, ATP-dependent proteases, and 
oligopeptidases. These proteases exert diverse functions, including 
mitochondrial protein folding, assembly, maturation and turnover, and 
elimination of defective proteins.  
Lon protease 
Short-lived regulatory proteins, oxidatively damaged proteins and misfolded 
proteins in mitochondrial matrix can be degraded by the Lon protease, a classic 
mitochondrial ATP-dependent protease. Human mitochondrial Lon protease is 
a huge homo-oligomeric complex, which contains three types of domains, an 
N-terminal domain, a central ATPase domain and a C-terminal proteolytic 
domain. The N-terminal domain is conceivable to be related to the selective 
binding of target substrates and oligomeric assembly of the whole protease 
complex, while the C-terminal domain exerts serine protease activity. The 
ATPase domain is involved in unfolding of substrates and ensuring the 
specificity of proteolysis with energy derived from ATP hydrolysis (Garcia-
Nafria et al., 2010). A group of mitochondrial chaperons can assist the 
recognition of substrates, prevent selected proteins from aggregation, and 
promote the proteolytic efficiency. Protein aggregation and accumulation have 
been found in mitochondria of cells with deficient Lon protease. Therefore, 
Lon proteases are crucial for mitochondrial protein quality surveillance, 
especially under stressed conditions, when the levels of abnormal and damaged 
proteins are increased (Kaser & Langer, 2000). It has been reported that Lon-
protease degrades aconitase oxidized by H2O2 in the mitochondrial matrix in 
beef heart muscle (Bota & Davies, 2002). 44 
ClpXP protease 
The ClpXP protease is the other ATP-dependent proteases in the matrix of 
mammalian mitochondria. In contrast to Lon proteases, little is known about 
their physiological role, but ClpXP proteases are still included in the 
mitochondrial protein quality control system. As hetero-oligomer, ClpXP 
protease consists of ClpP subunit exhibiting serine peptidase activity and ClpX 
subunit with ATPase and chaperone activity.  
AAA proteases 
Mitochondrial AAA proteases are ATP-dependent proteases and anchored 
within mitochondrial inner membrane. These proteases can degrade defective 
membrane-embedded polypeptides. Usually, AAA proteases exist in huge 
molecular mass complexes (approximately 1 MDa), consisting of closely 
related or identical subunits, which contain ATPase domains with similar 
functions as those in the Lon and ClpXP proteases (Kaser & Langer, 2000; 
Langer, 2000).  
All mitochondrial proteases described above constitute the first line of 
defense for the protection of mitochondrial integrity at molecular level. When 
the capability of these proteases is insufficient, other strategies are employed, 
i.e., mitochondrial fusion and fission. Constant fusion and fission provide a 
dynamic nature to mitochondria and supply an extra and essential protection 
against stress-mediated damage. Irreversibly damaged components can be 
segregated by fission and eliminated by autophagy. Severely impaired 
mitochondria are eliminated by autophagy, namely mitophagy, to protect cells 
from apoptosis triggered by abnormal mitochondria (Lionaki & Tavernarakis, 
2013; Youle & van der Bliek, 2012; Tatsuta & Langer, 2008).  45 
2 Present  investigations 
2.1  TK2 mutations in autosomal recessive progressive external 
ophthalmoplegia (Paper I) 
2.1.1  Aim of this study 
Two female patients were siblings of healthy, non-consanguineous parents and 
manifested typical PEO-associated symptoms from late 40s to early 50s. The 
aim of this study was to identify the genetic defects underlying the pathology 
and clinical features of these two patients. We also attempted to establish 
genotype-phenotype correlations in this form of arPEO. 
2.1.2 Results  and  discussion 
The mtDNA copy number in skeletal muscle sample of patient II:4 was 
determined and a relative mild mtDNA reduction (decreased by 40%) was 
observed in skeletal muscles, but it did not fulfill the consensus criteria (>60% 
impairment) of mtDNA depletion. By Southern blot analysis, multiple mtDNA 
deletions were detected in skeletal muscle tissue of patient II:5. Likewise, 
deleted mtDNA molecules were found in skeletal muscle and several regions 
of the brain but not in heart, liver or cerebellum in patient II:4. By direct 
sequencing, no pathogenic mutations were detected in neither the 
mitochondrial genome nor in the coding regions of any nuclear genes, which 
were known to be associated with PEO.  
To elucidate the genetic background of PEO in these two patients, whole-
exome next-generation sequencing technology was employed to sequence the 
coding regions of the nuclear genome of patient II:4. Compound heterozygous 
missense mutations c.673C>T and c.688A>G, which resulted in p.R225W and 
p.T230A, respectively (refseq accession no. NM_004614.3) in the TK2 gene 
were identified in both patients. The amino acid substitution at T230 was a 
novel mutation, while the R225W mutation has been reported previously as 46 
homozygous or compound heterozygous with T106M or R172W in Finnish 
and Swedish patients suffering from the myopathic form of MDS (Gotz et al., 
2008). The allele frequencies of the two mutations were assessed by screening 
400 healthy Finnish controls and only one heterozygous carrier of the T230A 
was identified. 
Multiple sequence alignment of TK2 exhibited that both T230 and R225 
residues were located within a highly conserved sequence regions. Due to the 
lack of structure information for TK2, we built a structure model by 
comparative protein modeling using the SWISS-MODEL computer algorithm 
with the structure of its homolog Dm-dNK (PDB entry 1OT3) as the template. 
In the structure model, R225 was located on the tip of β4 (Figure 4) and not 
involved in substrate binding directly. Instead, the substitution of R225 with a 
tryptophan is predicted to affect the binding affinity of the base moiety of ATP, 
due to the occupation of space and disturbance of hydrogen bond patterns by 
the bulkier side chain of the altered amino acid. Similarly, T230 located in α8, 
which forms the lid region with α9, was not directly engaged in substrate 
binding (Figure 4). Nonetheless, it interacted with R234 of the lid region, 
which is essential for the binding of the phosphate groups of ATP by hydrogen 
bonds. Thus, the substitution with alanine may very likely impair the catalytic 
efficiency of TK2.  47 
 
Figure 4. Structure model of truncated human TK2 (SwissPort O00142). Four cysteine residues 
are shown in red, while the Cys264 is not shown due to the truncation at the C-terminus of TK2 
model. The two residues, R183 and T188 (refseq accession no. NM_004614.4), discovered in the 
two patients suffering from arPEO, are presented in yellow. 
To evaluate the effects of the two mutations on the catalytic function of 
TK2, we constructed and expressed recombinant TK2 mutants in E. coli and 
characterized their kinetic parameters with the natural substrates dThd, dCyd 
and ATP, respectively. Compared with the wild type enzyme, both 
recombinant mutants had higher Km values for dThd and similar Km values 
when dCyd was the substrate. Due to the significant impairment in the Vmax 
values for both substrates, the catalytic efficiencies (Vmax/Km) of R225W and 
T230A decreased to 5.7% and 30.7% with dThd, respectively, and 7.8% 
respective 52.8% with dCyd. When ATP was the variable substrates, both 
mutant enzymes demonstrated similar reductions in catalytic efficiencies as 
those of dThd and dCyd. These results are consistent with predictions based on 48 
the structure model of TK2. On the other hand, the R225W mutation caused 
near-total loss-of-function of TK2 and thus the presence of homozygous 
R225W mutation should result in severe mtDNA depletion, which is in 
agreement with a previous clinical report (Gotz et al., 2008). We also 
determined the combined effects of the two mutants on total TK2 activity. The 
specific activity of TK2 mutants was 22% of the wild type TK2 activity at 
equal ratio, and decreased when the proportion of R225W was elevated (in a 
range of 2-38%).  
In addition, TK2 activity levels in mitochondria isolated from fibroblasts 
derived from both patients were also determined. The TK2 activities with dThd 
and dCyd were 22 and 28% of control values for patient II:4, respectively, and 
42% respective 54% of control values for patient II:5. The specificities of 
mitochondrial TK2 in patients towards dThd and dCyd were also altered 
compared with that of control. All these findings supported the conclusion that 
the compound heterozygous TK2 mutations were the cause of adult-onset 
arPEO in the patients investigated here. 
2.2  The kinetic effects on TK2 by enzyme-bound dTTP (Paper II) 
2.2.1  Aim of this study 
TK2 phosphorylates pyrimidine deoxynucleosides and their analogs, such as 
AZT to the corresponding 5’-monophosphate forms. AZT was reported to be a 
potent inhibitor of thymidine phosphorylation in isolated rat liver and heart 
mitochondria and this was suggested as the mechanism for the depletion of the 
mitochondrial dTTP pool, which was essential for mtDNA replication (Lynx & 
McKee, 2006). In this study, we investigated the effects of AZT and some 
other pyrimidine analogs on the phosphorylation of dThd and dCyd with 
human recombinant TK2 and partially purified native rat TK2 to test this 
hypothesis and clarify the mechanism of mitochondrial side effects caused by 
anti-viral thymidine analogs. 
2.2.2 Results  and  discussion 
First, the kinetic parameters of TK2 were determined with AZT and FLT as 
substrates by phosphoryl transfer assays. The Km values for AZT and FLT 
were 4.5 μM and 6.5 μM and the Vmax values were 28.9 and 23.5 nmol/min/mg, 
respectively. Thus, the overall catalytic efficiencies (Vmax/Km) of TK2 with 
AZT and FLT were only 2% respective 4% of that with dThd. Despite being 
poor substrates of TK2, AZT and FLT were able to inhibit competitively the 
phosphorylation of dThd by TK2, with Ki values of 3.0 and 1.4 μM, 
respectively. In contrast, approximate 30% stimulation of dCyd 49 
phosphorylation was observed in the presence of AZT or FLT, while slight 
inhibition was observed when the AZT or FLT concentration exceeded 100 μM. 
The other thymidine analogs d4T and araT had similar effects on the 
phosphorylation of dThd and dCyd as AZT, whereas deoxycytidine analogs 
3TC and ddC were not effective inhibitors at low concentrations. By multi-
inhibitor assays, we found that AZT and FLT completed with dThd for the 
same binding site of TK2 because the inhibitory effects of them were mutually 
exclusive. These results suggested that thymidine analogs would exert similar 
side effects associated with inhibition of pyrimidine nucleotide metabolism. 
To ensure that the properties described above were not artifact due to 
recombinant expression, native mitochondrial TK2 was prepared from rat liver 
and analyzed by mass spectrometry. It was showed that native rat TK2 had an 
apparent molecular weight of 28 kDa and 82% sequence identity with human 
TK2. For the purified native rat TK2, the apparent Km and Vmax values were 19 
μM and 70 pmol/min/mg for dThd, and 41 μM and 89 pmol/min/mg when 
dCyd was substrate. AZT and FLT also inhibited the phosphorylation of dThd 
with IC50 value of ~10 μM and stimulated dCyd phosphorylation more than 3 
folds. These results demonstrated that recombinant human TK2 and rat 
mitochondrial TK2 had similar kinetic properties. 
dTTP and dCTP are the feedback inhibitors of TK2 and have been shown to 
bind to recombinant TK2 (Barroso et al., 2005; Wang et al., 2003). Here, we 
found that TK2 was in most cases in a complex with approximately equimolar 
of dTTP, but not with other dNTPs. The TK2-bound dTTP could be removed 
by incubation with dThd or AZT and less efficiently with dCyd. Furthermore, 
the phosphorylation of dThd and dCyd by the dTTP-free TK2 was inhibited to 
a similar extent by AZT or FLT. Thus, these findings suggested that the 
presence of thymidine analogs released the dTTP inhibitor from the enzyme so 
that it could react efficiently with dThd or dCyd. On the other hand, these dThd 
analogs were poor substrates for TK2 and thus could not be converted to 
monophosphates. Consequently, dCyd phosphorylation benefits from the 
presence of AZT or FLT, leading to the observed stimulation. 
On the basis of the estimation from Vmax/Km values, TK2 should produce 
dTMP and dCMP in a ratio of 1:0.7. Due to different impact on dThd and dCyd 
phosphorylation by AZT, TK2 activity with dThd will decrease by ~50%, 
whereas phosphorylation of dCyd will be stimulated by ~30%. Therefore, this 
will eventually change the normal dTTP and dCTP pools and affected mtDNA 
replication and maintenance. Thus, our results support the hypothesis for the 
mechanism suggested by the previously findings that the treatment with AZT 
led to a 50% depletion of dTTP pool but had little effect on dCTP pool in 
perfused rat heart mitochondria (Morris et al., 2009). The investigation 50 
presented in paper II provided a novel kinetic mechanism concerning the 
effects of pyrimidine nucleoside analogs on TK2 function and can improve our 
understanding of nucleosides metabolism in mitochondria and mitochondrial 
toxicities of nucleoside analogs.  
2.3 S-glutathionylation  and  proteolytic degradation of TK2 
(Paper III) 
2.3.1  Aim of this study 
Reversible protein S-glutathionylation is a posttranslational modification of 
redox-sensitive protein thiol groups of cysteine residues and plays important 
roles in regulation of protein stability and activity. Located in mitochondria 
that are a major site of ROS/RNS generation, mature TK2 contains five 
cysteine residues which are potential targets of S-glutathionylation. In the 
present study, we investigated the effects of cysteine-based redox regulation on 
the activity and stability of TK2.  
2.3.2 Results  and  discussion 
The activity of pure recombinant TK2 increased in the presence of reducing 
agents such as dithiothreitol (DTT) and GSH, but was inhibited by GSSG, in 
particular at high concentrations. Further studies showed that TK2 could be 
glutathionylated spontaneously by GSSG but not by GSH and the reaction was 
reversed by DTT and enhanced by diamide, a thiol oxidizing compound. To 
determine which cysteine residues reacted with GSSG, each of the five 
cysteine residues was replaced by an alanine residue by site-directed 
mutagenesis and subsequent analysis showed that Cys189 and Cys264 were the 
sites of S-glutathionylation. Extracts from isolated rat liver and brain 
mitochondria treated with H2O2 were added to recombinant TK2 and we found 
that recombinant TK2 was S-glutathionylated only by extracts from liver 
mitochondria. These results showed that S-glutathionylation of recombinant 
TK2 occurred in vitro but only with extracts from certain tissues subjected to 
oxidative stress.  
To elucidate whether endogenous mitochondrial TK2 could be 
glutathionylated under stress condition, mitochondria were isolated from U2OS 
cells treated with H2O2. By using immunoprecipitation and Western-blot 
analysis, we detected that the level of S-glutathionylated TK2 in mitochondria 
from H2O2 treated cells was 3-5 times higher than that from untreated cells. 
The TK2 activity and protein level in U2OS mitochondria also decreased with 
increasing H2O2 concentrations. These results imply that under oxidative stress 51 
mitochondrial TK2 is S-glutathionylated, which down-regulates enzyme 
activity and TK2 protein levels.  
In mitochondria isolated from H2O2-treated U2OS cells, a time-dependent 
degradation of GSSG-treated recombinant TK2 was observed, which could be 
inhibited by the addition of PMSF, a serine protease inhibitor. Meanwhile, in 
control mitochondria, neither normal nor glutathionylated TK2 was degraded. 
Therefore, it was S-glutathionylation that caused the selective degradation of 
TK2 in mitochondria. Further studies demonstrated that S-glutathionylation of 
Cys189 was responsible for the selective degradation of TK2, which occurred 
only in mitochondria isolated from cells under oxidative stress.  
Enzyme kinetic studies of cysteine mutants and structure modeling 
exhibited that none of the cysteines was involved in direct binding of the 
substrates (Figure 4). Since Cys189 residue was located at the α8 helix which 
formed the lid region, mutations of Cys189 and Cys264 to alanine or serine 
had no significant effect on the Km values for dThd, however, the Km values of 
C189A, C189S and C264S mutants were lower than that of wild type TK2 
when dCyd was the substrate. Thus, S-glutathionylation of these cysteine 
residues would predominantly generate a structural effect on TK2, resulting in 
lower catalytic activity, particularly towards dCyd. Redox regulation of TK2 
may play a significant role in the synthesis of mtDNA precursors and thus the 
maintenance of normal mitochondrial function.  
 
2.4  Down-regulation of mitochondrial TK2 and dGK by 
nucleoside analogs (Paper IV) 
2.4.1  Aim of this investigation 
During oxidative stress, TK2 is glutathionylated by GSSG on Cys189, which 
leads to partial inactivation and rapid degradation of TK2. The Cys189 residue 
is conserved in dGK and dCK, but not in Dm-dNK. In paper IV, we 
investigated whether dGK and dCK were subjected to the same processes as 
TK2. Furthermore, the use of nucleoside analogs in anti-cancer and anti-viral 
therapies has been reported to induce oxidative stress (Amatore et al., 2010; 
Kline et al., 2009; Ferraresi et al., 2006). Here, we tried to answer the question 
if oxidative stress induced by AZT and ddI could cause down-regulation of 
TK2 and dGK, which could be part of the mechanism of the mitochondrial 
toxicity observed with these nucleoside analogs. 52 
2.4.2 Results  and  discussion 
We found that both human dGK and dCK were glutathionylated by GSSG in a 
concentration-dependent manner similar to TK2, but had different sensitivities 
to GSSG. No glutathionylation could be detected with human TK1 or Dm-dNK 
despite that they contained 11 and 3 cysteine residues, respectively. This 
modification resulted in decreased activities of TK2 and dGK, but surprisingly 
increased dCK activity. These results indicate that S-glutathionylation is a 
common regulatory mechanism for the activity and/or stability of TK2, dGK 
and possibly dCK. 
The effects of oxidative stress on dGK and TK2 were further investigated 
using U2OS cells and different oxidants e.g., H2O2, tertbutyl hydroperoxide 
(tBHP) and diamide. We observed that the levels of TK2 and dGK decreased 
significantly in the presence of these oxidants, while the control protein was 
unaffected. On the basis of these results, we conclude that both TK2 and dGK 
are affected by oxidative stress, which apparently leads to selectively 
degradation by mitochondrial proteases. To exclude the involvement of 
cytosolic proteases, we incubated mitoplasts isolated from U2OS cells with 
H2O2 in the presence or absence of MG132, which is a mitochondrial AAA
+ 
Lon protease inhibitor. It was observed that MG132 strongly inhibited the 
degradation of TK2 and dGK. Thus, the down-regulation of TK2 and dGK 
during oxidative stress was S-glutathionylation dependent and the 
mitochondrial Lon protease was most likely responsible for the selective 
degradation. 
AZT is known to provoke ROS/RNS production in some tissues and result 
in mtDNA oxidative damage, lipoperoxidation and GSH depletion, most likely 
contributing to AZT side effects. In paper IV, we studied whether 
mitochondrial TK2 and dGK were affected by the oxidative stress induced by 
AZT. The levels of mitochondrial TK2 and dGK decreased by 30% and 60% in 
the U2OS cells exposed to 20 μM AZT. In addition, a ~10% decrease was also 
observed in the level of the cytochrome c oxidase subunit II (COX II) encoded 
by mtDNA, while nuclear DNA encoded COX IV levels were not changed. 
The cytosolic TK1 and dCK levels were also not affected. These results 
strongly indicated that the presence of AZT leads to down-regulation of 
mitochondrial deoxynucleoside kinases via a similar mechanism as oxidant 
treatments.  
To elucidate whether other nucleoside analogs had similar effects, a purine 
analog, ddI was utilized for a comparison. ddI is known to induce 
mitochondrial toxicity but require a different activation mechanism. The 
treatment with ddI unexpectedly induced similar effects on mitochondrial TK2 
and dGK levels as those found with AZT. Although the mechanism of the ddI 53 
induced degradation of TK2 and dGK is unclear, these results suggested that 
oxidative stress could be also involved in this case. 
Uridine supplementation has been used successfully to remit the side effects 
of AZT in patients and addition of guanosine could protect human 
neuroblastoma cells against mitochondrial oxidative stress (Dal-Cim et al., 
2012). However, the mechanism of the protective effects of the nucleosides is 
poorly understood.  
In paper IV, results are presented of experiments with additions of uridine 
and guanosine to cells treated with AZT and ddI, respectively. It was found 
that uridine supplementation of AZT treated cells could restore the 
mitochondrial TK2 and dGK to original levels. Guanosine supplementation in 
ddI treated cells had similar effects. The COX II levels were also back to 
original levels in the presence of uridine and guanosine. These results indicated 
that AZT and ddI treatments may lead to oxidative stress and severe and 
specific TK2 and dGK deficiency in mitochondria. Uridine and guanosine were 
able to protect TK2 and dGK from the down-regulation induced by AZT and 
ddI, respectively, and thereby prevent mitochondrial toxicities of these 
nucleoside analogs. However, the mechanism of the generalized protective 
effect observed after the addition of these nucleosides on mitochondrial 
function is unknown. This investigation has extended the knowledge regarding 
the redox regulation of mitochondrial nucleoside kinases and mtDNA 
precursor metabolism, and may help to prevent the toxicities of nucleoside 
analogs used in chemotherapy.   
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3  Conclusions and future perspectives 
Investigations carried out in this thesis focused on the role of TK2 in dThd 
analogs-associated mitochondrial toxicities, TK2 mutations in arPEO and 
redox regulation, in particular S-glutathionylation of TK2 and dGK. The 
conclusions are as follows: 
 
  TK2 mutations are a novel cause of adult-onset arPEO. Mutations in 
genes involved in mtDNA precursors metabolism and mtDNA replication 
can cause diverse clinical phenotypes as manifestations of mtDNA 
depletion and deletion disorders. MDS-related genes should be screened 
as candidates when studying the genetic background of individuals 
harboring multiple mtDNA deletion disorders, and vice versa. 
 
  The phosphorylation of dThd and dCyd is inhibited and stimulated by 
dThd analogs, respectively, but is not affected by dCyd analogs. The 
apparent opposite kinetic effects on TK2 activity by dThd analogs result 
from their potencies in releasing enzyme-bound dTTP, which can disturb 
the relative rates of mt dTTP and dCTP pool synthesis in vivo.  
 
  During oxidative stress, a conserved cysteine residue (Cys189 in TK2), in 
the dCK/dGK enzyme family is S-glutathionylated by GSSG. This S-
glutathionylation decreases TK2 and dGK activity, but increases dCK 
activity. Furthermore, this oxidative modification leads to proteolytic 
degradation of TK2 and dGK in mitochondria. 
 
  Treatment of U2OS cells with AZT and ddI results in selective 
degradation of mitochondrial TK2 and dGK, most likely as a result of 
oxidative stress. Uridine and guanosine supplementations antagonize the 
impairments of the function of both these enzymes in vivo. 56 
 
  Nucleoside analogs used in chemotherapies inhibit TK2 and dGK activity, 
alter specificities of TK2 and dGK towards different substrates and induce 
oxidative stress and S-glutathionylation of TK2 and dGK, leading to 
degradation. This may be a major reason for depletion of mtDNA levels 
and mitochondrial toxicity in cells treated with nucleoside analogs. 
       
The results presented in this thesis provide new insights concerning the 
regulation of enzymes involved in mtDNA precursor metabolism and on the 
potential mechanisms underlying nucleoside analogs-induced mitochondrial 
toxicities. Future crystal structure determination of TK2 is needed to 
understand thoroughly the kinetic effects of nucleoside analogs on pyrimidine 
nucleoside phosphorylation by TK2 and the correlation of TK2 mutations and 
functional defects. These will be helpful to improve pro-drugs used in anti-
viral and anti-cancer chemotherapy. Meanwhile, the expression and regulation 
at the transcriptional, translational and post-translational levels of TK2 and 
dGK still remain unsettled. Future studies may provide insight regarding 
mechanisms of mtDNA precursor metabolism and homeostasis, and the 
relations between diverse phenotypes of tissue-specific mtDNA disorders and 
genetic/pharmacological backgrounds. Furthermore, past investigations on 
inherited mtDNA disorders mainly focused on the genetic alternations in 
mtDNA and nuclear genes, which have been identified to be involved in 
mitochondrial structure and function. More comprehensive whole genome-
wide screening and evaluation are essential to ascertain the genetic causes of 
mitochondrial diseases. 
 57 
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